---
title: "Blood–brain barrier dysfunction in multiple sclerosis (improved by vitamin D, etc.)"
slug: "bloodbrain-barrier-dysfunction-in-multiple-sclerosis-improved-by-vitamin-d-etc"
aliases:
  - "/Blood–brain+barrier+dysfunction+in+multiple+sclerosis+improved+by+vitamin+D+etc+–+Jan+2024"
  - "/tiki-index.php?page_id=14891"
date: 2023-12-16
categories:
  - "Multiple Sclerosis"
---



<!-- {maketoc Title=""} -->

---

#### Blood–brain barrier dysfunction in multiple sclerosis: causes, consequences, and potential effects of therapies

Lancet January, 2024DOI:https://doi.org/10.1016/S1474-4422(23)00377-0 PDF behind paywall

Bettina Zierfuss, PhD, Catherine Larochelle, MD PhD, Prof Alexandre Prat, MD PhD 

Summary

Established by brain endothelial cells, the  **blood–brain barrier**  (BBB) regulates the trafficking of molecules, restricts immune cell entry into the CNS, and has an active role in neurovascular coupling (the regulation of cerebral blood flow to support neuronal activity). In the early stages of multiple sclerosis, around the time of symptom onset, inflammatory BBB damage is accompanied by pathogenic immune cell infiltration into the CNS. In the later stages of multiple sclerosis, dysregulation of neurovascular coupling is associated with grey matter atrophy. 

Genetic and environmental factors associated with multiple sclerosis, including 

* dietary habits, 

* the gut microbiome, 

* and  **vitamin D**  concentrations, 

might contribute directly and indirectly to brain endothelial cell dysfunction. Damage to brain endothelial cells leads to an influx of deleterious molecules into the CNS, accelerating leakage across the BBB. Potential future therapeutic approaches might help to prevent BBB damage (eg, monoclonal antibodies targeting cell adhesion molecules and fibrinogen) and help to repair BBB dysfunction (eg, mesenchymal stromal cells) in people with multiple sclerosis.

##### 101 References

1.Wengler K Ha J Syritsyna O et al.

Abnormal  **blood–brain barrier**  water exchange in chronic multiple sclerosis lesions: a preliminary study.

Magn Reson Imaging. 2020; 70: 126-133

Scopus (7)

2.Freedman MS Devonshire V Duquette P et al.

Treatment optimization in multiple sclerosis: Canadian MS Working Group recommendations.

Can J Neurol Sci. 2020; 47: 437-455

Scopus (52)

3.Ramaglia V Rojas O Naouar I Gommerman JL

The ins and outs of central nervous system inflammation—lessons learned from multiple sclerosis.

Annu Rev Immunol. 2021; 39: 199-226

Scopus (22)

4.Proulx ST Engelhardt B

Central nervous system zoning: how brain barriers establish subdivisions for CNS immune privilege and immune surveillance.

J Intern Med. 2022; 292: 47-67

Scopus (16)

5.Bell AH Miller SL Castillo-Melendez M Malhotra A

The neurovascular unit: effects of brain insults during the perinatal period.

Front Neurosci. 2020; 131452

Scopus (79)

6.Spencer JI Bell JS DeLuca GC

Vascular pathology in multiple sclerosis: reframing pathogenesis around the  **blood–brain barrier** .

J Neurol Neurosurg Psychiatry. 2018; 89: 42-52

Scopus (89)

7.Munji RN Soung AL Weiner GA et al.

Profiling the mouse brain endothelial transcriptome in health and disease models reveals a core  **blood–brain barrier**  dysfunction module.

Nat Neurosci. 2019; 22: 1892-1902

Scopus (166)

8.Abadier M Lyck R

Pathways across the  **blood–brain barrier** .

in: Lyck R Enzmann G The  **blood–brain barrier**  and inflammation. Springer International Publishing, Cham2017: 187-211

9.Marchetti L Francisco D Soldati S et al.

ACKR1 favors transcellular over paracellular T-cell diapedesis across the  **blood–brain barrier**  in neuroinflammation in vitro.

Eur J Immunol. 2022; 52: 161-177

Scopus (8)

10.Broux B Zandee S Gowing E et al.

Interleukin-26, preferentially produced by TH17 lymphocytes, regulates CNS barrier function.

Neurol Neuroimmunol Neuroinflamm. 2020; 7: e870

Scopus (16)

11.Charabati M Grasmuck C Ghannam S et al.

DICAM promotes TH17 lymphocyte trafficking across the  **blood–brain barrier**  during autoimmune neuroinflammation.

Sci Transl Med. 2022; 14eabj0473

Scopus (18)

12.Fournier AP Tastet O Charabati M et al.

Single-cell transcriptomics identifies brain endothelium inflammatory networks in experimental autoimmune encephalomyelitis.

Neurol Neuroimmunol Neuroinflamm. 2022; 10e200046

13.Charabati M Zandee S Fournier AP et al.

MCAM+ brain endothelial cells contribute to neuroinflammation by recruiting pathogenic CD4+ T lymphocytes.

Brain. 2023; 146: 1483-1495

Scopus (5)

14.Fournier AP Zandee S Charabati M et al.

CLMP promotes leukocyte migration across brain barriers in multiple sclerosis.

Neurol Neuroimmunol Neuroinflamm. 2022; 9e200022

Scopus (3)

15.Michel L Grasmuck C Charabati M et al.

Activated leukocyte cell adhesion molecule regulates B lymphocyte migration across central nervous system barriers.

Sci Transl Med. 2019; 11eaaw0475

Scopus (38)

16.Wimmer I Tietz S Nishihara H et al.

PECAM-1 stabilizes  **blood–brain barrier**  integrity and favors paracellular T-cell diapedesis across the  **blood–brain barrier**  during neuroinflammation.

Front Immunol. 2019; 10: 711

Scopus (102)

17.Larochelle C Uphaus T Broux B et al.

EGFL7 reduces CNS inflammation in mouse.

Nat Commun. 2018; 9: 819

Scopus (29)

18.Goasdoué K Miller SM Colditz PB Björkman ST

Review: the  **blood–brain barrier** ; protecting the developing fetal brain.

Placenta. 2017; 54: 111-116

Scopus (89)

19.Delaney C Campbell M

The  **blood–brain barrier** : insights from development and ageing.

Tissue Barriers. 2017; 5e1373897

Scopus (21)

20.Skillbäck T Blennow K Zetterberg H et al.

Sex differences in CSF biomarkers for neurodegeneration and  **blood–brain barrier**  integrity.

Alzheimers Dement (Amst). 2021; 13e12141

21.Stamatovic SM Martinez-Revollar G Hu A Choi J Keep RF Andjelkovic AV

Decline in Sirtuin-1 expression and activity plays a critical role in  **blood–brain barrier**  permeability in aging.

Neurobiol Dis. 2019; 126: 105-116

Scopus (80)

22.Li Y Xie L Huang T et al.

Aging Neurovascular unit and potential role of dna damage and repair in combating vascular and neurodegenerative disorders.

Front Neurosci. 2019; 13: 778

Scopus (3)

23.Dobi A Rosanaly S Devin A et al.

Advanced glycation end-products disrupt brain microvascular endothelial cell barrier: the role of mitochondria and oxidative stress.

Microvasc Res. 2021; 133104098

Scopus (19)

24.D'Souza A Burch A Dave KM et al.

Microvesicles transfer mitochondria and increase mitochondrial function in brain endothelial cells.

J Control Release. 2021; 338: 505-526

Scopus (52)

25.Baranzini SE Oksenberg JR

The genetics of multiple sclerosis: from 0 to 200 in 50 years.

Trends Genet. 2017; 33: 960-970

Scopus (136)

Summary

Full Text

Full Text PDF

26.Jeong H-W Diéguez-Hurtado R Arf H et al.

Single-cell transcriptomics reveals functionally specialized vascular endothelium in brain.

eLife. 2022; 11e57520

27.Mohammadhosayni M Khosrojerdi A Lorian K et al.

Matrix metalloproteinases (MMPs) family gene polymorphisms and the risk of multiple sclerosis: systematic review and meta-analysis.

BMC Neurol. 2020; 20: 218

Scopus (10)

28.Patsopoulos NA Baranzini SE Santaniello A et al.

Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility.

Science. 2019; 365eaav7188

29.Logsdon AF Erickson MA Rhea EM Salameh TS Banks WA

Gut reactions: how the  **blood–brain barrier**  connects the microbiome and the brain.

Exp Biol Med (Maywood). 2018; 243: 159-165

Scopus (150)

30.Rhea EM Salameh TS Logsdon AF Hanson AJ Erickson MA Banks WA

 **blood–brain barrier** s in obesity.

AAPS J. 2017; 19: 921-930

Scopus (85)

31.Zhou X Baumann R Gao X et al.

Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course.

Cell. 2022; 185: 3467-3486

Scopus (46)

Summary

Full Text

Full Text PDF

32.Cantoni C Lin Q Dorsett Y et al.

Alterations of host–gut microbiome interactions in multiple sclerosis.

EBioMedicine. 2022; 76103798

Scopus (43)

Summary

Full Text

Full Text PDF

33.Bäcker-Koduah P Bellmann-Strobl J Scheel M et al.

 **vitamin D**  and disease severity in multiple sclerosis-baseline data from the randomized controlled trial (EVIDIMS).

Front Neurol. 2020; 11: 129

Scopus (11)

34.Cortese M Munger KL Martínez-Lapiscina EH et al.

 **vitamin D** , smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT.

Neurology. 2020; 94: e1950-e1960

Scopus (31)

35.Hupperts R Smolders J Vieth R et al.

Randomized trial of daily high-dose  **vitamin D3**  in patients with RRMS receiving subcutaneous interferon β-1a.

Neurology. 2019; 93: e1906-e1916

Scopus (74)

36.Bjornevik K Cortese M Healy BC et al.

Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.

Science. 2022; 375: 296-301

Scopus (647)

37.Tengvall K Huang J Hellström C et al.

Molecular mimicry between anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk.

Proc Natl Acad Sci USA. 2019; 116: 16955-16960

Scopus (86)

38.Lanz TV Brewer RC Ho PP et al.

Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM.

Nature. 2022; 603: 321-327

Scopus (251)

39.Zhang N Zuo Y Jiang L Peng Y Huang X Zuo L

Epstein-Barr virus and neurological diseases.

Front Mol Biosci. 2022; 8816098

Scopus (40)

40.Montgomery S Hiyoshi A Burkill S Alfredsson L Bahmanyar S Olsson T

Concussion in adolescence and risk of multiple sclerosis.

Ann Neurol. 2017; 82: 554-561

Scopus (37)

41.Degelman ML Herman KM

Smoking and multiple sclerosis: a systematic review and meta-analysis using the Bradford Hill criteria for causation.

Mult Scler Relat Disord. 2017; 17: 207-216

Scopus (91)

Summary

Full Text

Full Text PDF

42.Wu S-Y Xing F Sharma S et al.

Nicotine promotes brain metastasis by polarizing microglia and suppressing innate immune function.

J Exp Med. 2020; 217e20191131

Scopus (48)

43.Oakes JM Fuchs RM Gardner JD Lazartigues E Yue X

Nicotine and the renin–angiotensin system.

Am J Physiol Regul Integr Comp Physiol. 2018; 315: R895-R906

Scopus (199)

44.Olsson T Barcellos LF Alfredsson L

Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis.

Nat Rev Neurol. 2017; 13: 25-36

Scopus (636)

45.Zhang SL Yue Z Arnold DM Artiushin G Sehgal A

A circadian clock in the  **blood–brain barrier**  regulates xenobiotic efflux.

Cell. 2018; 173: 130-139.e10

Scopus (131)

Summary

Full Text

Full Text PDF

46.Cuddapah VA Zhang SL Sehgal A

Regulation of the  **blood–brain barrier**  by circadian rhythms and sleep.

Trends Neurosci. 2019; 42: 500-510

Scopus (99)

Summary

Full Text

Full Text PDF

47.Artiushin G Zhang SL Tricoire H Sehgal A

Endocytosis at the Drosophila  **blood–brain barrier**  as a function for sleep.

eLife. 2018; 7e43326

Scopus (49)

48.Sun J Wu J Hua F Chen Y Zhan F Xu G

Sleep deprivation induces cognitive impairment by increasing  **blood–brain barrier**  permeability via CD44.

Front Neurol. 2020; 11563916

Scopus (22)

49.Nishihara H Perriot S Gastfriend BD et al.

Intrinsic  **blood–brain barrier**  dysfunction contributes to multiple sclerosis pathogenesis.

Brain. 2022; 145: 4334-4348

Scopus (24)

50.Filippi M Brück W Chard D et al.

Association between pathological and MRI findings in multiple sclerosis.

Lancet Neurol. 2019; 18: 198-210

Scopus (144)

Summary

Full Text

Full Text PDF

51.Yong HYF Yong VW

Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis.

Nat Rev Neurol. 2022; 18: 40-55

Scopus (40)

52.Petersen MA Ryu JK Akassoglou K

Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics.

Nat Rev Neurosci. 2018; 19: 283-301

Scopus (256)

53.Yates RL Esiri MM Palace J Jacobs B Perera R DeLuca GC

Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex.

Ann Neurol. 2017; 82: 259-270

Scopus (77)

54.Ryu JK Rafalski VA Meyer-Franke A et al.

Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration.

Nat Immunol. 2018; 19: 1212-1223

Scopus (118)

55.Willis CM Nicaise AM Menoret A et al.

Extracellular vesicle fibrinogen induces encephalitogenic CD8+ T cells in a mouse model of multiple sclerosis.

Proc Natl Acad Sci USA. 2019; 116: 10488-10493

Scopus (30)

56.Brailoiu E Shipsky MM Yan G Abood ME Brailoiu GC

Mechanisms of modulation of brain microvascular endothelial cells function by thrombin.

Brain Res. 2017; 1657: 167-175

Scopus (40)

57.Suthiphosuwan S Sati P Absinta M et al.

Paramagnetic rim sign in radiologically isolated syndrome.

JAMA Neurol. 2020; 77: 653-655

Scopus (32)

58.Hagemeier J Ramanathan M Schweser F et al.

Iron-related gene variants and brain iron in multiple sclerosis and healthy individuals.

Neuroimage Clin. 2017; 17: 530-540

Scopus (27)

59.Sweeney MD Zhao Z Montagne A Nelson AR Zlokovic BV

 **blood–brain barrier** : from physiology to disease and back.

Physiol Rev. 2019; 99: 21-78

Scopus (1043)

60.Benedict RHB Amato MP DeLuca J Geurts JJG

Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues.

Lancet Neurol. 2020; 19: 860-871

Scopus (237)

Summary

Full Text

Full Text PDF

61.Granziera C Wuerfel J Barkhof F et al.

Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis.

Brain. 2021; 144: 1296-1311

Scopus (58)

62.Sivakolundu DK West KL Maruthy GB et al.

Reduced arterial compliance along the cerebrovascular tree predicts cognitive slowing in multiple sclerosis: Evidence for a neurovascular uncoupling hypothesis.

Mult Scler. 2020; 26: 1486-1496

Scopus (13)

63.Barro C Benkert P Disanto G et al.

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.

Brain. 2018; 141: 2382-2391

Scopus (300)

64.Uher T McComb M Galkin S et al.

Neurofilament levels are associated with  **blood–brain barrier**  integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis.

Mult Scler. 2021; 27: 220-231

Scopus (41)

65.Sejbaek T Nielsen HH Penner N et al.

Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients.

J Neurol Neurosurg Psychiatry. 2019; 90: 1324-1330

66.Kuhle J Plavina T Barro C et al.

Neurofilament light levels are associated with long-term outcomes in multiple sclerosis.

Mult Scler. 2020; 26: 1691-1699

Scopus (57)

67.Hyun J-W Kim Y Kim G Kim S-H Kim HJ

Longitudinal analysis of serum neurofilament light chain: a potential therapeutic monitoring biomarker for multiple sclerosis.

Mult Scler. 2020; 26: 659-667

Scopus (21)

68.Sandelius Å Zetterberg H Blennow K et al.

Plasma neurofilament light chain concentration in the inherited peripheral neuropathies.

Neurology. 2018; 90: e518-e524

Scopus (162)

69.Kalm M Boström M Sandelius Å et al.

Serum concentrations of the axonal injury marker neurofilament light protein are not influenced by  **blood–brain barrier**  permeability.

Brain Res. 2017; 1668: 12-19

Scopus (44)

70.Watanabe M Nakamura Y Michalak Z et al.

Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.

Neurology. 2019; 93: e1299-e1311

Scopus (112)

71.Papa L Ladde JG O'Brien JF et al.

Evaluation of glial and neuronal blood biomarkers compared with clinical decision rules in assessing the need for computed tomography in patients with mild traumatic brain injury.

JAMA Netw Open. 2022; 5e221302

Scopus (14)

72.Brambilla R

The contribution of astrocytes to the neuroinflammatory response in multiple sclerosis and experimental autoimmune encephalomyelitis.

Acta Neuropathol. 2019; 137: 757-783

Scopus (139)

73.Martinsen V Kursula P

Multiple sclerosis and myelin basic protein: insights into protein disorder and disease.

Amino Acids. 2022; 54: 99-109

Scopus (42)

74.Nohejlova H Kayserova J Capek V Toman T Krsek P Liba Z

Paediatric onset of multiple sclerosis: analysis of chemokine and cytokine levels in the context of the early clinical course.

Mult Scler Relat Disord. 2020; 46102467

Scopus (5)

Summary

Full Text

Full Text PDF

75.Wang D Duan H Feng J et al.

Soluble CD146, a cerebrospinal fluid marker for neuroinflammation, promotes  **blood–brain barrier**  dysfunction.

Theranostics. 2020; 10: 231-246

Scopus (21)

76.Ziliotto N Lamberti N Manfredini F et al.

Baseline and overtime variations of soluble adhesion molecule plasma concentrations are associated with mobility recovery after rehabilitation in multiple sclerosis patients.

J Neuroimmunol. 2021; 352577473

Scopus (2)

Summary

Full Text

Full Text PDF

77.Fournier AP Quenault A Martinez de Lizarrondo S et al.

Prediction of disease activity in models of multiple sclerosis by molecular magnetic resonance imaging of P-selectin.

Proc Natl Acad Sci USA. 2017; 114: 6116-6121

Scopus (37)

78.Masuda H Mori M Uchida T Uzawa A Ohtani R Kuwabara S

Soluble CD40 ligand contributes to  **blood–brain barrier**  breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder.

J Neuroimmunol. 2017; 305: 102-107

Scopus (32)

Summary

Full Text

Full Text PDF

79.Agah E Zardoui A Saghazadeh A Ahmadi M Tafakhori A Rezaei N

Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: a systematic review and meta-analysis.

PLoS One. 2018; 13e0190252

Scopus (52)

80.Spitzer D Puetz T Armbrust M et al.

Anti-osteopontin therapy leads to improved edema and infarct size in a murine model of ischemic stroke.

Sci Rep. 2022; 1220925

Scopus (2)

81.Clemente N Comi C Raineri D et al.

Role of anti-osteopontin antibodies in multiple sclerosis and experimental autoimmune encephalomyelitis.

Front Immunol. 2017; 8: 321

Scopus (29)

82.Çiçekli E Sayan S Kotan D

Availability of fibrinogen/albumin ratio in MS attack.

Mult Scler Relat Disord. 2022; 60103674

Scopus (4)

Summary

Full Text

Full Text PDF

83.Miranda Acuña J Hidalgo de la Cruz M Ros AL Tapia SP Martínez Ginés ML de Andrés Frutos CD

Elevated plasma fibrinogen levels in multiple sclerosis patients during relapse.

Mult Scler Relat Disord. 2017; 18: 157-160

Scopus (17)

Summary

Full Text

Full Text PDF

84.Schaller-Paule MA Yalachkov Y Steinmetz H et al.

Analysis of CSF D-dimer to identify intrathecal fibrin-driven autoimmunity in patients with multiple sclerosis.

Neurol Neuroimmunol Neuroinflamm. 2022; 9e1150

Scopus (5)

85.Balasa R Barcutean L Mosora O Manu D

Reviewing the significance of  **blood–brain barrier**  disruption in multiple sclerosis pathology and treatment.

Int J Mol Sci. 2021; 228370

Scopus (40)

86.Pyka-Fosciak G Lis GJ Litwin JA

Effect of natalizumab treatment on metalloproteinases and their inhibitors in a mouse model of multiple sclerosis.

J Physiol Pharmacol. 2020; 71: 265-273

87.Knudsen MH Lindberg U Frederiksen JL et al.

 **blood–brain barrier**  permeability changes in the first year after alemtuzumab treatment predict 2-year outcomes in relapsing-remitting multiple sclerosis.

Mult Scler Relat Disord. 2022; 63103891

Scopus (5)

Summary

Full Text

Full Text PDF

88.Nguyen K Juillard P Hawke S Grau GE Marsh-Wakefield F

Trans-endothelial migration of memory T Cells is impaired in alemtuzumab-treated multiple sclerosis patients.

J Clin Med. 2022; 116266

Scopus (1)

89.Ford RK Juillard P Hawke S Grau GE Marsh-Wakefield F

Cladribine reduces trans-endothelial migration of memory T cells across an in vitro  **blood–brain barrier** .

J Clin Med. 2022; 116006

Scopus (4)

90.Sellebjerg F Blinkenberg M Sorensen PS

Anti-CD20 monoclonal antibodies for relapsing and progressive multiple sclerosis.

CNS Drugs. 2020; 34: 269-280

Scopus (42)

91.Krämer J Bar-Or A Turner TJ Wiendl H

Bruton tyrosine kinase inhibitors for multiple sclerosis.

Nat Rev Neurol. 2023; 19: 289-304

Scopus (9)

92.Banoth B Cassel SL

Bruton tyrosine kinase inhibition: clinical relevance beyond B cells.

J Allergy Clin Immunol. 2017; 140: 985-987

Scopus (8)

Summary

Full Text

Full Text PDF

93.Mizuno M Noto D Kaga N Chiba A Miyake S

The dual role of short fatty acid chains in the pathogenesis of autoimmune disease models.

PLoS One. 2017; 12e0173032

Scopus (149)

94.Dai Y Wei T Shen Z Bei Y Lin H Dai H

Classical HDACs in the regulation of neuroinflammation.

Neurochem Int. 2021; 150105182

Scopus (16)

95.Shen Y Yang R Zhao J et al.

The histone deacetylase inhibitor belinostat ameliorates experimental autoimmune encephalomyelitis in mice by inhibiting TLR2/MyD88 and HDAC3/NF-κB p65-mediated neuroinflammation.

Pharmacol Res. 2022; 176105969

Scopus (15)

96.Buonvicino D Ranieri G Chiarugi A

Treatment with non-specific HDAC inhibitors administered after disease onset does not delay evolution in a mouse model of progressive multiple sclerosis.

Neuroscience. 2021; 465: 38-45

Scopus (6)

Summary

Full Text

Full Text PDF

97.Ghaiad HR Nooh MM El-Sawalhi MM Shaheen AA

Resveratrol promotes remyelination in cuprizone model of multiple sclerosis: biochemical and histological study.

Mol Neurobiol. 2017; 54: 3219-3229

Scopus (85)

98.Boffa G Lapucci C Sbragia E et al.

Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab.

Eur J Neurol. 2020; 27: 2047-2055

Scopus (13)

99.Roudi S Rädler JA El Andaloussi S

Therapeutic potential of extracellular vesicles in neurodegenerative disorders.

Handb Clin Neurol. 2023; 193: 243-266

Scopus (0)

100.Hayakawa K Chan SJ Mandeville ET et al.

Protective effects of endothelial progenitor cell-derived extracellular mitochondria in brain endothelium.

Stem Cells. 2018; 36: 1404-1410

Scopus (91)

101.Charabati M Rabanel J-M Ramassamy C Prat A

Overcoming the brain barriers: from immune cells to nanoparticles.

Trends Pharmacol Sci. 2020; 41: 42-54

Scopus (27)

---

#### 28,000 hits for "blood brain barrier" "vitamin d" in Google Scholar

 **https://scholar.google.com/scholar?hl=en&as_sdt=0%2C48&q=%22blood+brain+barrier%22+%22vitamin+d%22&btnG=|Google Scholar]** 

* Active form of vitamin D directly protects the blood–brain barrier in multiple sclerosis-  August 2017 https://doi.org/10.1111/cen3.12398  FREE PDF

* Full spectrum of vitamin D immunomodulation in multiple sclerosis: mechanisms and therapeutic implications - June 2022  https://doi.org/10.1093/braincomms/fcac171 FREE PDF

  * "In this review, we focus on recent published data describing the biological effects of Vitamin D in animal models of multiple sclerosis on immune cells, blood–brain barrier function, activation of glial cells and its potential neuroprotective effects."

* The Role of Vitamin D in Neuroprotection in Multiple Sclerosis: An Update - June 2023  https://doi.org/10.3390/nu15132978 FREE PDF

* Intranasal administration of vitamin D attenuates blood–brain barrier disruption through endogenous upregulation of osteopontin and activation of CD44/P-gp glycosylation signaling after subarachnoid hemorrhage in rats - Oct 2016 https://doi.org/10.1177/0271678X16671147 FREE PDF

  * Note: VitaminDWiki has been successfully experimenting in inhaing Vitamin D since about 2015

---

#### VitaminDWiki – <a href="/posts/multiple-sclerosis-32-percent-less-likely-among-those-with-more-than-32-ng-of-vitamin-d" style="color: red; text-decoration: underline;" title="This post/category does not exist yet: Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019">Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019</a>

---

#### See Brain in VitaminDWiki

* <a href="/posts/brain-and-vitamin-d-many-studies" style="color: red; text-decoration: underline;" title="This post/category does not exist yet: Brain and Vitamin D - many studies">Brain and Vitamin D - many studies</a>

* [Global burden of brain disorders surpasses cardiovascular disease and cancer - July 2023](/posts/global-burden-of-brain-disorders-surpasses-cardiovascular-disease-and-cancer)

  * Contains: Vitamin D inhaled thru the nose gets some directly to the brain

* <a href="/posts/vitamin-d3-attenuates-blood-brain-barrier-disruption-due-to-tbi-in-rats" style="color: red; text-decoration: underline;" title="This post/category does not exist yet: Vitamin D3 Attenuates Blood-Brain Barrier Disruption due to TBI (in rats) – Feb 2021">Vitamin D3 Attenuates Blood-Brain Barrier Disruption due to TBI (in rats) – Feb 2021</a>

* [Many Neurological Diseases fought by Vitamin D - Dec 2022](/posts/many-neurological-diseases-fought-by-vitamin-d)

---

#### See also in VitaminDWiki

* [Multiple Sclerosis risk factors - Vitamin D was the only one you can easily change - Sept 2023](/posts/multiple-sclerosis-risk-factors-vitamin-d-was-the-only-one-you-can-easily-change)

* [Multiple Sclerosis prevention with high-dose vitamin D (in rats in this case) - July 2023](/posts/multiple-sclerosis-prevention-with-high-dose-vitamin-d-in-rats-in-this-case)

* <a href="/posts/diseases-treated-by-high-dose-vitamin-d-many-studies" style="color: red; text-decoration: underline;" title="This post/category does not exist yet: Diseases treated by high-dose Vitamin D - many studies">Diseases treated by high-dose Vitamin D - many studies</a>

* <a href="/posts/an-opportunity-use-vitamin-d-to-treat-multiple-sclerosis-has-been-used-for-14-years" style="color: red; text-decoration: underline;" title="This post/category does not exist yet: An opportunity - use Vitamin D to treat Multiple Sclerosis (has been used for 14 years) - Feb 2022">An opportunity - use Vitamin D to treat Multiple Sclerosis (has been used for 14 years) - Feb 2022</a>

---

#### VitaminDWiki – <a href="/posts/overview-ms-and-vitamin-d" style="color: red; text-decoration: underline;" title="This post/category does not exist yet: Overview MS and vitamin D">Overview MS and vitamin D</a> contains

<!-- ~tc~ (alias(Blood–brain barrier dysfunction in multiple sclerosis (improved by vitamin D, etc.) – Jan 2023)) ~/tc~ -->


<pre style="background-color: #e0e0e0;">
<code class="language-text">
Markdown:
--------

&lt;!-- {maketoc Title=&quot;&quot;} --&gt;

---

#### Blood–brain barrier dysfunction in multiple sclerosis: causes, consequences, and potential effects of therapies

Lancet January, 2024DOI:https://doi.org/10.1016/S1474-4422(23)00377-0 PDF behind paywall

Bettina Zierfuss, PhD, Catherine Larochelle, MD PhD, Prof Alexandre Prat, MD PhD 

Summary

Established by brain endothelial cells, the  **blood–brain barrier**  (BBB) regulates the trafficking of molecules, restricts immune cell entry into the CNS, and has an active role in neurovascular coupling (the regulation of cerebral blood flow to support neuronal activity). In the early stages of multiple sclerosis, around the time of symptom onset, inflammatory BBB damage is accompanied by pathogenic immune cell infiltration into the CNS. In the later stages of multiple sclerosis, dysregulation of neurovascular coupling is associated with grey matter atrophy. 

Genetic and environmental factors associated with multiple sclerosis, including 

* dietary habits, 

* the gut microbiome, 

* and  **vitamin D**  concentrations, 

might contribute directly and indirectly to brain endothelial cell dysfunction. Damage to brain endothelial cells leads to an influx of deleterious molecules into the CNS, accelerating leakage across the BBB. Potential future therapeutic approaches might help to prevent BBB damage (eg, monoclonal antibodies targeting cell adhesion molecules and fibrinogen) and help to repair BBB dysfunction (eg, mesenchymal stromal cells) in people with multiple sclerosis.

##### 101 References

1.Wengler K Ha J Syritsyna O et al.

Abnormal  **blood–brain barrier**  water exchange in chronic multiple sclerosis lesions: a preliminary study.

Magn Reson Imaging. 2020; 70: 126-133

Scopus (7)

2.Freedman MS Devonshire V Duquette P et al.

Treatment optimization in multiple sclerosis: Canadian MS Working Group recommendations.

Can J Neurol Sci. 2020; 47: 437-455

Scopus (52)

3.Ramaglia V Rojas O Naouar I Gommerman JL

The ins and outs of central nervous system inflammation—lessons learned from multiple sclerosis.

Annu Rev Immunol. 2021; 39: 199-226

Scopus (22)

4.Proulx ST Engelhardt B

Central nervous system zoning: how brain barriers establish subdivisions for CNS immune privilege and immune surveillance.

J Intern Med. 2022; 292: 47-67

Scopus (16)

5.Bell AH Miller SL Castillo-Melendez M Malhotra A

The neurovascular unit: effects of brain insults during the perinatal period.

Front Neurosci. 2020; 131452

Scopus (79)

6.Spencer JI Bell JS DeLuca GC

Vascular pathology in multiple sclerosis: reframing pathogenesis around the  **blood–brain barrier** .

J Neurol Neurosurg Psychiatry. 2018; 89: 42-52

Scopus (89)

7.Munji RN Soung AL Weiner GA et al.

Profiling the mouse brain endothelial transcriptome in health and disease models reveals a core  **blood–brain barrier**  dysfunction module.

Nat Neurosci. 2019; 22: 1892-1902

Scopus (166)

8.Abadier M Lyck R

Pathways across the  **blood–brain barrier** .

in: Lyck R Enzmann G The  **blood–brain barrier**  and inflammation. Springer International Publishing, Cham2017: 187-211

9.Marchetti L Francisco D Soldati S et al.

ACKR1 favors transcellular over paracellular T-cell diapedesis across the  **blood–brain barrier**  in neuroinflammation in vitro.

Eur J Immunol. 2022; 52: 161-177

Scopus (8)

10.Broux B Zandee S Gowing E et al.

Interleukin-26, preferentially produced by TH17 lymphocytes, regulates CNS barrier function.

Neurol Neuroimmunol Neuroinflamm. 2020; 7: e870

Scopus (16)

11.Charabati M Grasmuck C Ghannam S et al.

DICAM promotes TH17 lymphocyte trafficking across the  **blood–brain barrier**  during autoimmune neuroinflammation.

Sci Transl Med. 2022; 14eabj0473

Scopus (18)

12.Fournier AP Tastet O Charabati M et al.

Single-cell transcriptomics identifies brain endothelium inflammatory networks in experimental autoimmune encephalomyelitis.

Neurol Neuroimmunol Neuroinflamm. 2022; 10e200046

13.Charabati M Zandee S Fournier AP et al.

MCAM+ brain endothelial cells contribute to neuroinflammation by recruiting pathogenic CD4+ T lymphocytes.

Brain. 2023; 146: 1483-1495

Scopus (5)

14.Fournier AP Zandee S Charabati M et al.

CLMP promotes leukocyte migration across brain barriers in multiple sclerosis.

Neurol Neuroimmunol Neuroinflamm. 2022; 9e200022

Scopus (3)

15.Michel L Grasmuck C Charabati M et al.

Activated leukocyte cell adhesion molecule regulates B lymphocyte migration across central nervous system barriers.

Sci Transl Med. 2019; 11eaaw0475

Scopus (38)

16.Wimmer I Tietz S Nishihara H et al.

PECAM-1 stabilizes  **blood–brain barrier**  integrity and favors paracellular T-cell diapedesis across the  **blood–brain barrier**  during neuroinflammation.

Front Immunol. 2019; 10: 711

Scopus (102)

17.Larochelle C Uphaus T Broux B et al.

EGFL7 reduces CNS inflammation in mouse.

Nat Commun. 2018; 9: 819

Scopus (29)

18.Goasdoué K Miller SM Colditz PB Björkman ST

Review: the  **blood–brain barrier** ; protecting the developing fetal brain.

Placenta. 2017; 54: 111-116

Scopus (89)

19.Delaney C Campbell M

The  **blood–brain barrier** : insights from development and ageing.

Tissue Barriers. 2017; 5e1373897

Scopus (21)

20.Skillbäck T Blennow K Zetterberg H et al.

Sex differences in CSF biomarkers for neurodegeneration and  **blood–brain barrier**  integrity.

Alzheimers Dement (Amst). 2021; 13e12141

21.Stamatovic SM Martinez-Revollar G Hu A Choi J Keep RF Andjelkovic AV

Decline in Sirtuin-1 expression and activity plays a critical role in  **blood–brain barrier**  permeability in aging.

Neurobiol Dis. 2019; 126: 105-116

Scopus (80)

22.Li Y Xie L Huang T et al.

Aging Neurovascular unit and potential role of dna damage and repair in combating vascular and neurodegenerative disorders.

Front Neurosci. 2019; 13: 778

Scopus (3)

23.Dobi A Rosanaly S Devin A et al.

Advanced glycation end-products disrupt brain microvascular endothelial cell barrier: the role of mitochondria and oxidative stress.

Microvasc Res. 2021; 133104098

Scopus (19)

24.D&#39;Souza A Burch A Dave KM et al.

Microvesicles transfer mitochondria and increase mitochondrial function in brain endothelial cells.

J Control Release. 2021; 338: 505-526

Scopus (52)

25.Baranzini SE Oksenberg JR

The genetics of multiple sclerosis: from 0 to 200 in 50 years.

Trends Genet. 2017; 33: 960-970

Scopus (136)

Summary

Full Text

Full Text PDF

26.Jeong H-W Diéguez-Hurtado R Arf H et al.

Single-cell transcriptomics reveals functionally specialized vascular endothelium in brain.

eLife. 2022; 11e57520

27.Mohammadhosayni M Khosrojerdi A Lorian K et al.

Matrix metalloproteinases (MMPs) family gene polymorphisms and the risk of multiple sclerosis: systematic review and meta-analysis.

BMC Neurol. 2020; 20: 218

Scopus (10)

28.Patsopoulos NA Baranzini SE Santaniello A et al.

Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility.

Science. 2019; 365eaav7188

29.Logsdon AF Erickson MA Rhea EM Salameh TS Banks WA

Gut reactions: how the  **blood–brain barrier**  connects the microbiome and the brain.

Exp Biol Med (Maywood). 2018; 243: 159-165

Scopus (150)

30.Rhea EM Salameh TS Logsdon AF Hanson AJ Erickson MA Banks WA

 **blood–brain barrier** s in obesity.

AAPS J. 2017; 19: 921-930

Scopus (85)

31.Zhou X Baumann R Gao X et al.

Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course.

Cell. 2022; 185: 3467-3486

Scopus (46)

Summary

Full Text

Full Text PDF

32.Cantoni C Lin Q Dorsett Y et al.

Alterations of host–gut microbiome interactions in multiple sclerosis.

EBioMedicine. 2022; 76103798

Scopus (43)

Summary

Full Text

Full Text PDF

33.Bäcker-Koduah P Bellmann-Strobl J Scheel M et al.

 **vitamin D**  and disease severity in multiple sclerosis-baseline data from the randomized controlled trial (EVIDIMS).

Front Neurol. 2020; 11: 129

Scopus (11)

34.Cortese M Munger KL Martínez-Lapiscina EH et al.

 **vitamin D** , smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT.

Neurology. 2020; 94: e1950-e1960

Scopus (31)

35.Hupperts R Smolders J Vieth R et al.

Randomized trial of daily high-dose  **vitamin D3**  in patients with RRMS receiving subcutaneous interferon β-1a.

Neurology. 2019; 93: e1906-e1916

Scopus (74)

36.Bjornevik K Cortese M Healy BC et al.

Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.

Science. 2022; 375: 296-301

Scopus (647)

37.Tengvall K Huang J Hellström C et al.

Molecular mimicry between anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk.

Proc Natl Acad Sci USA. 2019; 116: 16955-16960

Scopus (86)

38.Lanz TV Brewer RC Ho PP et al.

Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM.

Nature. 2022; 603: 321-327

Scopus (251)

39.Zhang N Zuo Y Jiang L Peng Y Huang X Zuo L

Epstein-Barr virus and neurological diseases.

Front Mol Biosci. 2022; 8816098

Scopus (40)

40.Montgomery S Hiyoshi A Burkill S Alfredsson L Bahmanyar S Olsson T

Concussion in adolescence and risk of multiple sclerosis.

Ann Neurol. 2017; 82: 554-561

Scopus (37)

41.Degelman ML Herman KM

Smoking and multiple sclerosis: a systematic review and meta-analysis using the Bradford Hill criteria for causation.

Mult Scler Relat Disord. 2017; 17: 207-216

Scopus (91)

Summary

Full Text

Full Text PDF

42.Wu S-Y Xing F Sharma S et al.

Nicotine promotes brain metastasis by polarizing microglia and suppressing innate immune function.

J Exp Med. 2020; 217e20191131

Scopus (48)

43.Oakes JM Fuchs RM Gardner JD Lazartigues E Yue X

Nicotine and the renin–angiotensin system.

Am J Physiol Regul Integr Comp Physiol. 2018; 315: R895-R906

Scopus (199)

44.Olsson T Barcellos LF Alfredsson L

Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis.

Nat Rev Neurol. 2017; 13: 25-36

Scopus (636)

45.Zhang SL Yue Z Arnold DM Artiushin G Sehgal A

A circadian clock in the  **blood–brain barrier**  regulates xenobiotic efflux.

Cell. 2018; 173: 130-139.e10

Scopus (131)

Summary

Full Text

Full Text PDF

46.Cuddapah VA Zhang SL Sehgal A

Regulation of the  **blood–brain barrier**  by circadian rhythms and sleep.

Trends Neurosci. 2019; 42: 500-510

Scopus (99)

Summary

Full Text

Full Text PDF

47.Artiushin G Zhang SL Tricoire H Sehgal A

Endocytosis at the Drosophila  **blood–brain barrier**  as a function for sleep.

eLife. 2018; 7e43326

Scopus (49)

48.Sun J Wu J Hua F Chen Y Zhan F Xu G

Sleep deprivation induces cognitive impairment by increasing  **blood–brain barrier**  permeability via CD44.

Front Neurol. 2020; 11563916

Scopus (22)

49.Nishihara H Perriot S Gastfriend BD et al.

Intrinsic  **blood–brain barrier**  dysfunction contributes to multiple sclerosis pathogenesis.

Brain. 2022; 145: 4334-4348

Scopus (24)

50.Filippi M Brück W Chard D et al.

Association between pathological and MRI findings in multiple sclerosis.

Lancet Neurol. 2019; 18: 198-210

Scopus (144)

Summary

Full Text

Full Text PDF

51.Yong HYF Yong VW

Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis.

Nat Rev Neurol. 2022; 18: 40-55

Scopus (40)

52.Petersen MA Ryu JK Akassoglou K

Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics.

Nat Rev Neurosci. 2018; 19: 283-301

Scopus (256)

53.Yates RL Esiri MM Palace J Jacobs B Perera R DeLuca GC

Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex.

Ann Neurol. 2017; 82: 259-270

Scopus (77)

54.Ryu JK Rafalski VA Meyer-Franke A et al.

Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration.

Nat Immunol. 2018; 19: 1212-1223

Scopus (118)

55.Willis CM Nicaise AM Menoret A et al.

Extracellular vesicle fibrinogen induces encephalitogenic CD8+ T cells in a mouse model of multiple sclerosis.

Proc Natl Acad Sci USA. 2019; 116: 10488-10493

Scopus (30)

56.Brailoiu E Shipsky MM Yan G Abood ME Brailoiu GC

Mechanisms of modulation of brain microvascular endothelial cells function by thrombin.

Brain Res. 2017; 1657: 167-175

Scopus (40)

57.Suthiphosuwan S Sati P Absinta M et al.

Paramagnetic rim sign in radiologically isolated syndrome.

JAMA Neurol. 2020; 77: 653-655

Scopus (32)

58.Hagemeier J Ramanathan M Schweser F et al.

Iron-related gene variants and brain iron in multiple sclerosis and healthy individuals.

Neuroimage Clin. 2017; 17: 530-540

Scopus (27)

59.Sweeney MD Zhao Z Montagne A Nelson AR Zlokovic BV

 **blood–brain barrier** : from physiology to disease and back.

Physiol Rev. 2019; 99: 21-78

Scopus (1043)

60.Benedict RHB Amato MP DeLuca J Geurts JJG

Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues.

Lancet Neurol. 2020; 19: 860-871

Scopus (237)

Summary

Full Text

Full Text PDF

61.Granziera C Wuerfel J Barkhof F et al.

Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis.

Brain. 2021; 144: 1296-1311

Scopus (58)

62.Sivakolundu DK West KL Maruthy GB et al.

Reduced arterial compliance along the cerebrovascular tree predicts cognitive slowing in multiple sclerosis: Evidence for a neurovascular uncoupling hypothesis.

Mult Scler. 2020; 26: 1486-1496

Scopus (13)

63.Barro C Benkert P Disanto G et al.

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.

Brain. 2018; 141: 2382-2391

Scopus (300)

64.Uher T McComb M Galkin S et al.

Neurofilament levels are associated with  **blood–brain barrier**  integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis.

Mult Scler. 2021; 27: 220-231

Scopus (41)

65.Sejbaek T Nielsen HH Penner N et al.

Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients.

J Neurol Neurosurg Psychiatry. 2019; 90: 1324-1330

66.Kuhle J Plavina T Barro C et al.

Neurofilament light levels are associated with long-term outcomes in multiple sclerosis.

Mult Scler. 2020; 26: 1691-1699

Scopus (57)

67.Hyun J-W Kim Y Kim G Kim S-H Kim HJ

Longitudinal analysis of serum neurofilament light chain: a potential therapeutic monitoring biomarker for multiple sclerosis.

Mult Scler. 2020; 26: 659-667

Scopus (21)

68.Sandelius Å Zetterberg H Blennow K et al.

Plasma neurofilament light chain concentration in the inherited peripheral neuropathies.

Neurology. 2018; 90: e518-e524

Scopus (162)

69.Kalm M Boström M Sandelius Å et al.

Serum concentrations of the axonal injury marker neurofilament light protein are not influenced by  **blood–brain barrier**  permeability.

Brain Res. 2017; 1668: 12-19

Scopus (44)

70.Watanabe M Nakamura Y Michalak Z et al.

Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.

Neurology. 2019; 93: e1299-e1311

Scopus (112)

71.Papa L Ladde JG O&#39;Brien JF et al.

Evaluation of glial and neuronal blood biomarkers compared with clinical decision rules in assessing the need for computed tomography in patients with mild traumatic brain injury.

JAMA Netw Open. 2022; 5e221302

Scopus (14)

72.Brambilla R

The contribution of astrocytes to the neuroinflammatory response in multiple sclerosis and experimental autoimmune encephalomyelitis.

Acta Neuropathol. 2019; 137: 757-783

Scopus (139)

73.Martinsen V Kursula P

Multiple sclerosis and myelin basic protein: insights into protein disorder and disease.

Amino Acids. 2022; 54: 99-109

Scopus (42)

74.Nohejlova H Kayserova J Capek V Toman T Krsek P Liba Z

Paediatric onset of multiple sclerosis: analysis of chemokine and cytokine levels in the context of the early clinical course.

Mult Scler Relat Disord. 2020; 46102467

Scopus (5)

Summary

Full Text

Full Text PDF

75.Wang D Duan H Feng J et al.

Soluble CD146, a cerebrospinal fluid marker for neuroinflammation, promotes  **blood–brain barrier**  dysfunction.

Theranostics. 2020; 10: 231-246

Scopus (21)

76.Ziliotto N Lamberti N Manfredini F et al.

Baseline and overtime variations of soluble adhesion molecule plasma concentrations are associated with mobility recovery after rehabilitation in multiple sclerosis patients.

J Neuroimmunol. 2021; 352577473

Scopus (2)

Summary

Full Text

Full Text PDF

77.Fournier AP Quenault A Martinez de Lizarrondo S et al.

Prediction of disease activity in models of multiple sclerosis by molecular magnetic resonance imaging of P-selectin.

Proc Natl Acad Sci USA. 2017; 114: 6116-6121

Scopus (37)

78.Masuda H Mori M Uchida T Uzawa A Ohtani R Kuwabara S

Soluble CD40 ligand contributes to  **blood–brain barrier**  breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder.

J Neuroimmunol. 2017; 305: 102-107

Scopus (32)

Summary

Full Text

Full Text PDF

79.Agah E Zardoui A Saghazadeh A Ahmadi M Tafakhori A Rezaei N

Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: a systematic review and meta-analysis.

PLoS One. 2018; 13e0190252

Scopus (52)

80.Spitzer D Puetz T Armbrust M et al.

Anti-osteopontin therapy leads to improved edema and infarct size in a murine model of ischemic stroke.

Sci Rep. 2022; 1220925

Scopus (2)

81.Clemente N Comi C Raineri D et al.

Role of anti-osteopontin antibodies in multiple sclerosis and experimental autoimmune encephalomyelitis.

Front Immunol. 2017; 8: 321

Scopus (29)

82.Çiçekli E Sayan S Kotan D

Availability of fibrinogen/albumin ratio in MS attack.

Mult Scler Relat Disord. 2022; 60103674

Scopus (4)

Summary

Full Text

Full Text PDF

83.Miranda Acuña J Hidalgo de la Cruz M Ros AL Tapia SP Martínez Ginés ML de Andrés Frutos CD

Elevated plasma fibrinogen levels in multiple sclerosis patients during relapse.

Mult Scler Relat Disord. 2017; 18: 157-160

Scopus (17)

Summary

Full Text

Full Text PDF

84.Schaller-Paule MA Yalachkov Y Steinmetz H et al.

Analysis of CSF D-dimer to identify intrathecal fibrin-driven autoimmunity in patients with multiple sclerosis.

Neurol Neuroimmunol Neuroinflamm. 2022; 9e1150

Scopus (5)

85.Balasa R Barcutean L Mosora O Manu D

Reviewing the significance of  **blood–brain barrier**  disruption in multiple sclerosis pathology and treatment.

Int J Mol Sci. 2021; 228370

Scopus (40)

86.Pyka-Fosciak G Lis GJ Litwin JA

Effect of natalizumab treatment on metalloproteinases and their inhibitors in a mouse model of multiple sclerosis.

J Physiol Pharmacol. 2020; 71: 265-273

87.Knudsen MH Lindberg U Frederiksen JL et al.

 **blood–brain barrier**  permeability changes in the first year after alemtuzumab treatment predict 2-year outcomes in relapsing-remitting multiple sclerosis.

Mult Scler Relat Disord. 2022; 63103891

Scopus (5)

Summary

Full Text

Full Text PDF

88.Nguyen K Juillard P Hawke S Grau GE Marsh-Wakefield F

Trans-endothelial migration of memory T Cells is impaired in alemtuzumab-treated multiple sclerosis patients.

J Clin Med. 2022; 116266

Scopus (1)

89.Ford RK Juillard P Hawke S Grau GE Marsh-Wakefield F

Cladribine reduces trans-endothelial migration of memory T cells across an in vitro  **blood–brain barrier** .

J Clin Med. 2022; 116006

Scopus (4)

90.Sellebjerg F Blinkenberg M Sorensen PS

Anti-CD20 monoclonal antibodies for relapsing and progressive multiple sclerosis.

CNS Drugs. 2020; 34: 269-280

Scopus (42)

91.Krämer J Bar-Or A Turner TJ Wiendl H

Bruton tyrosine kinase inhibitors for multiple sclerosis.

Nat Rev Neurol. 2023; 19: 289-304

Scopus (9)

92.Banoth B Cassel SL

Bruton tyrosine kinase inhibition: clinical relevance beyond B cells.

J Allergy Clin Immunol. 2017; 140: 985-987

Scopus (8)

Summary

Full Text

Full Text PDF

93.Mizuno M Noto D Kaga N Chiba A Miyake S

The dual role of short fatty acid chains in the pathogenesis of autoimmune disease models.

PLoS One. 2017; 12e0173032

Scopus (149)

94.Dai Y Wei T Shen Z Bei Y Lin H Dai H

Classical HDACs in the regulation of neuroinflammation.

Neurochem Int. 2021; 150105182

Scopus (16)

95.Shen Y Yang R Zhao J et al.

The histone deacetylase inhibitor belinostat ameliorates experimental autoimmune encephalomyelitis in mice by inhibiting TLR2/MyD88 and HDAC3/NF-κB p65-mediated neuroinflammation.

Pharmacol Res. 2022; 176105969

Scopus (15)

96.Buonvicino D Ranieri G Chiarugi A

Treatment with non-specific HDAC inhibitors administered after disease onset does not delay evolution in a mouse model of progressive multiple sclerosis.

Neuroscience. 2021; 465: 38-45

Scopus (6)

Summary

Full Text

Full Text PDF

97.Ghaiad HR Nooh MM El-Sawalhi MM Shaheen AA

Resveratrol promotes remyelination in cuprizone model of multiple sclerosis: biochemical and histological study.

Mol Neurobiol. 2017; 54: 3219-3229

Scopus (85)

98.Boffa G Lapucci C Sbragia E et al.

Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab.

Eur J Neurol. 2020; 27: 2047-2055

Scopus (13)

99.Roudi S Rädler JA El Andaloussi S

Therapeutic potential of extracellular vesicles in neurodegenerative disorders.

Handb Clin Neurol. 2023; 193: 243-266

Scopus (0)

100.Hayakawa K Chan SJ Mandeville ET et al.

Protective effects of endothelial progenitor cell-derived extracellular mitochondria in brain endothelium.

Stem Cells. 2018; 36: 1404-1410

Scopus (91)

101.Charabati M Rabanel J-M Ramassamy C Prat A

Overcoming the brain barriers: from immune cells to nanoparticles.

Trends Pharmacol Sci. 2020; 41: 42-54

Scopus (27)

---

#### 28,000 hits for &quot;blood brain barrier&quot; &quot;vitamin d&quot; in Google Scholar

 **https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C48&amp;q=%22blood+brain+barrier%22+%22vitamin+d%22&amp;btnG=|Google Scholar]** 

* Active form of vitamin D directly protects the blood–brain barrier in multiple sclerosis-  August 2017 https://doi.org/10.1111/cen3.12398  FREE PDF

* Full spectrum of vitamin D immunomodulation in multiple sclerosis: mechanisms and therapeutic implications - June 2022  https://doi.org/10.1093/braincomms/fcac171 FREE PDF

  * &quot;In this review, we focus on recent published data describing the biological effects of Vitamin D in animal models of multiple sclerosis on immune cells, blood–brain barrier function, activation of glial cells and its potential neuroprotective effects.&quot;

* The Role of Vitamin D in Neuroprotection in Multiple Sclerosis: An Update - June 2023  https://doi.org/10.3390/nu15132978 FREE PDF

* Intranasal administration of vitamin D attenuates blood–brain barrier disruption through endogenous upregulation of osteopontin and activation of CD44/P-gp glycosylation signaling after subarachnoid hemorrhage in rats - Oct 2016 https://doi.org/10.1177/0271678X16671147 FREE PDF

  * Note: VitaminDWiki has been successfully experimenting in inhaing Vitamin D since about 2015

---

#### VitaminDWiki – &lt;a href=&quot;/posts/multiple-sclerosis-32-percent-less-likely-among-those-with-more-than-32-ng-of-vitamin-d&quot; style=&quot;color: red; text-decoration: underline;&quot; title=&quot;This post/category does not exist yet: Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019&quot;&gt;Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019&lt;/a&gt;

---

#### See Brain in VitaminDWiki

* &lt;a href=&quot;/posts/brain-and-vitamin-d-many-studies&quot; style=&quot;color: red; text-decoration: underline;&quot; title=&quot;This post/category does not exist yet: Brain and Vitamin D - many studies&quot;&gt;Brain and Vitamin D - many studies&lt;/a&gt;

* [Global burden of brain disorders surpasses cardiovascular disease and cancer - July 2023](/posts/global-burden-of-brain-disorders-surpasses-cardiovascular-disease-and-cancer)

  * Contains: Vitamin D inhaled thru the nose gets some directly to the brain

* &lt;a href=&quot;/posts/vitamin-d3-attenuates-blood-brain-barrier-disruption-due-to-tbi-in-rats&quot; style=&quot;color: red; text-decoration: underline;&quot; title=&quot;This post/category does not exist yet: Vitamin D3 Attenuates Blood-Brain Barrier Disruption due to TBI (in rats) – Feb 2021&quot;&gt;Vitamin D3 Attenuates Blood-Brain Barrier Disruption due to TBI (in rats) – Feb 2021&lt;/a&gt;

* [Many Neurological Diseases fought by Vitamin D - Dec 2022](/posts/many-neurological-diseases-fought-by-vitamin-d)

---

#### See also in VitaminDWiki

* [Multiple Sclerosis risk factors - Vitamin D was the only one you can easily change - Sept 2023](/posts/multiple-sclerosis-risk-factors-vitamin-d-was-the-only-one-you-can-easily-change)

* [Multiple Sclerosis prevention with high-dose vitamin D (in rats in this case) - July 2023](/posts/multiple-sclerosis-prevention-with-high-dose-vitamin-d-in-rats-in-this-case)

* &lt;a href=&quot;/posts/diseases-treated-by-high-dose-vitamin-d-many-studies&quot; style=&quot;color: red; text-decoration: underline;&quot; title=&quot;This post/category does not exist yet: Diseases treated by high-dose Vitamin D - many studies&quot;&gt;Diseases treated by high-dose Vitamin D - many studies&lt;/a&gt;

* &lt;a href=&quot;/posts/an-opportunity-use-vitamin-d-to-treat-multiple-sclerosis-has-been-used-for-14-years&quot; style=&quot;color: red; text-decoration: underline;&quot; title=&quot;This post/category does not exist yet: An opportunity - use Vitamin D to treat Multiple Sclerosis (has been used for 14 years) - Feb 2022&quot;&gt;An opportunity - use Vitamin D to treat Multiple Sclerosis (has been used for 14 years) - Feb 2022&lt;/a&gt;

---

#### VitaminDWiki – &lt;a href=&quot;/posts/overview-ms-and-vitamin-d&quot; style=&quot;color: red; text-decoration: underline;&quot; title=&quot;This post/category does not exist yet: Overview MS and vitamin D&quot;&gt;Overview MS and vitamin D&lt;/a&gt; contains

&lt;!-- ~tc~ (alias(Blood–brain barrier dysfunction in multiple sclerosis (improved by vitamin D, etc.) – Jan 2023)) ~/tc~ --&gt;


AST Structure:
-------------
├── DivNode
│   full_match: `{DIV(class=&quot;lefth4&quot;)}{maketoc Title=&quot;&quot;}{DIV}`
│   inner_content: `{maketoc Title=&quot;&quot;}`
│   attrs_dict:
│   │   raw_content: (class=&quot;lefth4&quot;)
│   │   class: lefth4
│   children:
│   ├── MakeTocNode
│   │   full_match: `{maketoc Title=&quot;&quot;}`
│   │   inner_content: ``
│   │   attrs_dict:
│   │   │   raw_content:  Title=&quot;&quot;
│   │   │   Title: ├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!Blood–brain barrier dysfunction in multiple sclerosis: causes, consequences, and potential effects of therapies`
│   inner_content: `Blood–brain barrier dysfunction in multiple sclerosis: causes, consequences, and potential effects of therapies`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `Blood–brain barrier dysfunction in multiple sclerosis: causes, consequences, and potential effects of therapies`
│   │   inner_content: `Blood–brain barrier dysfunction in multiple sclerosis: causes, consequences, and potential effects of therapies`├── TextNode
│   full_match: `\nLancet January, 2024DOI:https://doi.org/10.1016/S1474-4422(23)00377-0 PDF behind paywall\nBettina Zierfuss, PhD, Catherine Larochelle, MD PhD, Prof Alexandre Prat, MD PhD \n\nSummary\nEstablished by brain endothelial cells, the `
│   inner_content: `\nLancet January, 2024DOI:https://doi.org/10.1016/S1474-4422(23)00377-0 PDF behind paywall\nBettina Zierfuss, PhD, Catherine Larochelle, MD PhD, Prof Alexandre Prat, MD PhD \n\nSummary\nEstablished by brain endothelial cells, the `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: ` (BBB) regulates the trafficking of molecules, restricts immune cell entry into the CNS, and has an active role in neurovascular coupling (the regulation of cerebral blood flow to support neuronal activity). In the early stages of multiple sclerosis, around the time of symptom onset, inflammatory BBB damage is accompanied by pathogenic immune cell infiltration into the CNS. In the later stages of multiple sclerosis, dysregulation of neurovascular coupling is associated with grey matter atrophy. \nGenetic and environmental factors associated with multiple sclerosis, including \n`
│   inner_content: ` (BBB) regulates the trafficking of molecules, restricts immune cell entry into the CNS, and has an active role in neurovascular coupling (the regulation of cerebral blood flow to support neuronal activity). In the early stages of multiple sclerosis, around the time of symptom onset, inflammatory BBB damage is accompanied by pathogenic immune cell infiltration into the CNS. In the later stages of multiple sclerosis, dysregulation of neurovascular coupling is associated with grey matter atrophy. \nGenetic and environmental factors associated with multiple sclerosis, including \n`├── ListItemNode
│   full_match: `*dietary habits, `
│   inner_content: `dietary habits, `
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `dietary habits, `
│   │   inner_content: `dietary habits, `├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── ListItemNode
│   full_match: `*the gut microbiome, `
│   inner_content: `the gut microbiome, `
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `the gut microbiome, `
│   │   inner_content: `the gut microbiome, `├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── ListItemNode
│   full_match: `*and __vitamin D__ concentrations, `
│   inner_content: `and __vitamin D__ concentrations, `
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `and `
│   │   inner_content: `and `
│   ├── BoldNode
│   │   full_match: `__vitamin D__`
│   │   inner_content: `vitamin D`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `vitamin D`
│   │   │   inner_content: `vitamin D`
│   ├── TextNode
│   │   full_match: ` concentrations, `
│   │   inner_content: ` concentrations, `├── TextNode
│   full_match: `\nmight contribute directly and indirectly to brain endothelial cell dysfunction. Damage to brain endothelial cells leads to an influx of deleterious molecules into the CNS, accelerating leakage across the BBB. Potential future therapeutic approaches might help to prevent BBB damage (eg, monoclonal antibodies targeting cell adhesion molecules and fibrinogen) and help to repair BBB dysfunction (eg, mesenchymal stromal cells) in people with multiple sclerosis.\n`
│   inner_content: `\nmight contribute directly and indirectly to brain endothelial cell dysfunction. Damage to brain endothelial cells leads to an influx of deleterious molecules into the CNS, accelerating leakage across the BBB. Potential future therapeutic approaches might help to prevent BBB damage (eg, monoclonal antibodies targeting cell adhesion molecules and fibrinogen) and help to repair BBB dysfunction (eg, mesenchymal stromal cells) in people with multiple sclerosis.\n`├── HeadingNode
│   full_match: `!!!!!101 References`
│   inner_content: `101 References`
│   level: `5`
│   children:
│   ├── TextNode
│   │   full_match: `101 References`
│   │   inner_content: `101 References`├── TextNode
│   full_match: `\n1.Wengler K Ha J Syritsyna O et al.\nAbnormal `
│   inner_content: `\n1.Wengler K Ha J Syritsyna O et al.\nAbnormal `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: ` water exchange in chronic multiple sclerosis lesions: a preliminary study.\nMagn Reson Imaging. 2020; 70: 126-133\nScopus (7)\n2.Freedman MS Devonshire V Duquette P et al.\nTreatment optimization in multiple sclerosis: Canadian MS Working Group recommendations.\nCan J Neurol Sci. 2020; 47: 437-455\nScopus (52)\n3.Ramaglia V Rojas O Naouar I Gommerman JL\nThe ins and outs of central nervous system inflammation—lessons learned from multiple sclerosis.\nAnnu Rev Immunol. 2021; 39: 199-226\nScopus (22)\n4.Proulx ST Engelhardt B\nCentral nervous system zoning: how brain barriers establish subdivisions for CNS immune privilege and immune surveillance.\nJ Intern Med. 2022; 292: 47-67\nScopus (16)\n5.Bell AH Miller SL Castillo-Melendez M Malhotra A\nThe neurovascular unit: effects of brain insults during the perinatal period.\nFront Neurosci. 2020; 131452\nScopus (79)\n6.Spencer JI Bell JS DeLuca GC\nVascular pathology in multiple sclerosis: reframing pathogenesis around the `
│   inner_content: ` water exchange in chronic multiple sclerosis lesions: a preliminary study.\nMagn Reson Imaging. 2020; 70: 126-133\nScopus (7)\n2.Freedman MS Devonshire V Duquette P et al.\nTreatment optimization in multiple sclerosis: Canadian MS Working Group recommendations.\nCan J Neurol Sci. 2020; 47: 437-455\nScopus (52)\n3.Ramaglia V Rojas O Naouar I Gommerman JL\nThe ins and outs of central nervous system inflammation—lessons learned from multiple sclerosis.\nAnnu Rev Immunol. 2021; 39: 199-226\nScopus (22)\n4.Proulx ST Engelhardt B\nCentral nervous system zoning: how brain barriers establish subdivisions for CNS immune privilege and immune surveillance.\nJ Intern Med. 2022; 292: 47-67\nScopus (16)\n5.Bell AH Miller SL Castillo-Melendez M Malhotra A\nThe neurovascular unit: effects of brain insults during the perinatal period.\nFront Neurosci. 2020; 131452\nScopus (79)\n6.Spencer JI Bell JS DeLuca GC\nVascular pathology in multiple sclerosis: reframing pathogenesis around the `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: `.\nJ Neurol Neurosurg Psychiatry. 2018; 89: 42-52\nScopus (89)\n7.Munji RN Soung AL Weiner GA et al.\nProfiling the mouse brain endothelial transcriptome in health and disease models reveals a core `
│   inner_content: `.\nJ Neurol Neurosurg Psychiatry. 2018; 89: 42-52\nScopus (89)\n7.Munji RN Soung AL Weiner GA et al.\nProfiling the mouse brain endothelial transcriptome in health and disease models reveals a core `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: ` dysfunction module.\nNat Neurosci. 2019; 22: 1892-1902\nScopus (166)\n8.Abadier M Lyck R\nPathways across the `
│   inner_content: ` dysfunction module.\nNat Neurosci. 2019; 22: 1892-1902\nScopus (166)\n8.Abadier M Lyck R\nPathways across the `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: `.\nin: Lyck R Enzmann G The `
│   inner_content: `.\nin: Lyck R Enzmann G The `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: ` and inflammation. Springer International Publishing, Cham2017: 187-211\n9.Marchetti L Francisco D Soldati S et al.\nACKR1 favors transcellular over paracellular T-cell diapedesis across the `
│   inner_content: ` and inflammation. Springer International Publishing, Cham2017: 187-211\n9.Marchetti L Francisco D Soldati S et al.\nACKR1 favors transcellular over paracellular T-cell diapedesis across the `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: ` in neuroinflammation in vitro.\nEur J Immunol. 2022; 52: 161-177\nScopus (8)\n10.Broux B Zandee S Gowing E et al.\nInterleukin-26, preferentially produced by TH17 lymphocytes, regulates CNS barrier function.\nNeurol Neuroimmunol Neuroinflamm. 2020; 7: e870\nScopus (16)\n11.Charabati M Grasmuck C Ghannam S et al.\nDICAM promotes TH17 lymphocyte trafficking across the `
│   inner_content: ` in neuroinflammation in vitro.\nEur J Immunol. 2022; 52: 161-177\nScopus (8)\n10.Broux B Zandee S Gowing E et al.\nInterleukin-26, preferentially produced by TH17 lymphocytes, regulates CNS barrier function.\nNeurol Neuroimmunol Neuroinflamm. 2020; 7: e870\nScopus (16)\n11.Charabati M Grasmuck C Ghannam S et al.\nDICAM promotes TH17 lymphocyte trafficking across the `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: ` during autoimmune neuroinflammation.\nSci Transl Med. 2022; 14eabj0473\nScopus (18)\n12.Fournier AP Tastet O Charabati M et al.\nSingle-cell transcriptomics identifies brain endothelium inflammatory networks in experimental autoimmune encephalomyelitis.\nNeurol Neuroimmunol Neuroinflamm. 2022; 10e200046\n13.Charabati M Zandee S Fournier AP et al.\nMCAM+ brain endothelial cells contribute to neuroinflammation by recruiting pathogenic CD4+ T lymphocytes.\nBrain. 2023; 146: 1483-1495\nScopus (5)\n14.Fournier AP Zandee S Charabati M et al.\nCLMP promotes leukocyte migration across brain barriers in multiple sclerosis.\nNeurol Neuroimmunol Neuroinflamm. 2022; 9e200022\nScopus (3)\n15.Michel L Grasmuck C Charabati M et al.\nActivated leukocyte cell adhesion molecule regulates B lymphocyte migration across central nervous system barriers.\nSci Transl Med. 2019; 11eaaw0475\nScopus (38)\n16.Wimmer I Tietz S Nishihara H et al.\nPECAM-1 stabilizes `
│   inner_content: ` during autoimmune neuroinflammation.\nSci Transl Med. 2022; 14eabj0473\nScopus (18)\n12.Fournier AP Tastet O Charabati M et al.\nSingle-cell transcriptomics identifies brain endothelium inflammatory networks in experimental autoimmune encephalomyelitis.\nNeurol Neuroimmunol Neuroinflamm. 2022; 10e200046\n13.Charabati M Zandee S Fournier AP et al.\nMCAM+ brain endothelial cells contribute to neuroinflammation by recruiting pathogenic CD4+ T lymphocytes.\nBrain. 2023; 146: 1483-1495\nScopus (5)\n14.Fournier AP Zandee S Charabati M et al.\nCLMP promotes leukocyte migration across brain barriers in multiple sclerosis.\nNeurol Neuroimmunol Neuroinflamm. 2022; 9e200022\nScopus (3)\n15.Michel L Grasmuck C Charabati M et al.\nActivated leukocyte cell adhesion molecule regulates B lymphocyte migration across central nervous system barriers.\nSci Transl Med. 2019; 11eaaw0475\nScopus (38)\n16.Wimmer I Tietz S Nishihara H et al.\nPECAM-1 stabilizes `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: ` integrity and favors paracellular T-cell diapedesis across the `
│   inner_content: ` integrity and favors paracellular T-cell diapedesis across the `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: ` during neuroinflammation.\nFront Immunol. 2019; 10: 711\nScopus (102)\n17.Larochelle C Uphaus T Broux B et al.\nEGFL7 reduces CNS inflammation in mouse.\nNat Commun. 2018; 9: 819\nScopus (29)\n18.Goasdoué K Miller SM Colditz PB Björkman ST\nReview: the `
│   inner_content: ` during neuroinflammation.\nFront Immunol. 2019; 10: 711\nScopus (102)\n17.Larochelle C Uphaus T Broux B et al.\nEGFL7 reduces CNS inflammation in mouse.\nNat Commun. 2018; 9: 819\nScopus (29)\n18.Goasdoué K Miller SM Colditz PB Björkman ST\nReview: the `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: `; protecting the developing fetal brain.\nPlacenta. 2017; 54: 111-116\nScopus (89)\n19.Delaney C Campbell M\nThe `
│   inner_content: `; protecting the developing fetal brain.\nPlacenta. 2017; 54: 111-116\nScopus (89)\n19.Delaney C Campbell M\nThe `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: `: insights from development and ageing.\nTissue Barriers. 2017; 5e1373897\nScopus (21)\n20.Skillbäck T Blennow K Zetterberg H et al.\nSex differences in CSF biomarkers for neurodegeneration and `
│   inner_content: `: insights from development and ageing.\nTissue Barriers. 2017; 5e1373897\nScopus (21)\n20.Skillbäck T Blennow K Zetterberg H et al.\nSex differences in CSF biomarkers for neurodegeneration and `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: ` integrity.\nAlzheimers Dement (Amst). 2021; 13e12141\n21.Stamatovic SM Martinez-Revollar G Hu A Choi J Keep RF Andjelkovic AV\nDecline in Sirtuin-1 expression and activity plays a critical role in `
│   inner_content: ` integrity.\nAlzheimers Dement (Amst). 2021; 13e12141\n21.Stamatovic SM Martinez-Revollar G Hu A Choi J Keep RF Andjelkovic AV\nDecline in Sirtuin-1 expression and activity plays a critical role in `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: ` permeability in aging.\nNeurobiol Dis. 2019; 126: 105-116\nScopus (80)\n22.Li Y Xie L Huang T et al.\nAging Neurovascular unit and potential role of dna damage and repair in combating vascular and neurodegenerative disorders.\nFront Neurosci. 2019; 13: 778\nScopus (3)\n23.Dobi A Rosanaly S Devin A et al.\nAdvanced glycation end-products disrupt brain microvascular endothelial cell barrier: the role of mitochondria and oxidative stress.\nMicrovasc Res. 2021; 133104098\nScopus (19)\n24.D&#39;Souza A Burch A Dave KM et al.\nMicrovesicles transfer mitochondria and increase mitochondrial function in brain endothelial cells.\nJ Control Release. 2021; 338: 505-526\nScopus (52)\n25.Baranzini SE Oksenberg JR\nThe genetics of multiple sclerosis: from 0 to 200 in 50 years.\nTrends Genet. 2017; 33: 960-970\nScopus (136)\nSummary\nFull Text\nFull Text PDF\n26.Jeong H-W Diéguez-Hurtado R Arf H et al.\nSingle-cell transcriptomics reveals functionally specialized vascular endothelium in brain.\neLife. 2022; 11e57520\n27.Mohammadhosayni M Khosrojerdi A Lorian K et al.\nMatrix metalloproteinases (MMPs) family gene polymorphisms and the risk of multiple sclerosis: systematic review and meta-analysis.\nBMC Neurol. 2020; 20: 218\nScopus (10)\n28.Patsopoulos NA Baranzini SE Santaniello A et al.\nMultiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility.\nScience. 2019; 365eaav7188\n29.Logsdon AF Erickson MA Rhea EM Salameh TS Banks WA\nGut reactions: how the `
│   inner_content: ` permeability in aging.\nNeurobiol Dis. 2019; 126: 105-116\nScopus (80)\n22.Li Y Xie L Huang T et al.\nAging Neurovascular unit and potential role of dna damage and repair in combating vascular and neurodegenerative disorders.\nFront Neurosci. 2019; 13: 778\nScopus (3)\n23.Dobi A Rosanaly S Devin A et al.\nAdvanced glycation end-products disrupt brain microvascular endothelial cell barrier: the role of mitochondria and oxidative stress.\nMicrovasc Res. 2021; 133104098\nScopus (19)\n24.D&#39;Souza A Burch A Dave KM et al.\nMicrovesicles transfer mitochondria and increase mitochondrial function in brain endothelial cells.\nJ Control Release. 2021; 338: 505-526\nScopus (52)\n25.Baranzini SE Oksenberg JR\nThe genetics of multiple sclerosis: from 0 to 200 in 50 years.\nTrends Genet. 2017; 33: 960-970\nScopus (136)\nSummary\nFull Text\nFull Text PDF\n26.Jeong H-W Diéguez-Hurtado R Arf H et al.\nSingle-cell transcriptomics reveals functionally specialized vascular endothelium in brain.\neLife. 2022; 11e57520\n27.Mohammadhosayni M Khosrojerdi A Lorian K et al.\nMatrix metalloproteinases (MMPs) family gene polymorphisms and the risk of multiple sclerosis: systematic review and meta-analysis.\nBMC Neurol. 2020; 20: 218\nScopus (10)\n28.Patsopoulos NA Baranzini SE Santaniello A et al.\nMultiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility.\nScience. 2019; 365eaav7188\n29.Logsdon AF Erickson MA Rhea EM Salameh TS Banks WA\nGut reactions: how the `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: ` connects the microbiome and the brain.\nExp Biol Med (Maywood). 2018; 243: 159-165\nScopus (150)\n30.Rhea EM Salameh TS Logsdon AF Hanson AJ Erickson MA Banks WA\n`
│   inner_content: ` connects the microbiome and the brain.\nExp Biol Med (Maywood). 2018; 243: 159-165\nScopus (150)\n30.Rhea EM Salameh TS Logsdon AF Hanson AJ Erickson MA Banks WA\n`├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: `s in obesity.\nAAPS J. 2017; 19: 921-930\nScopus (85)\n31.Zhou X Baumann R Gao X et al.\nGut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course.\nCell. 2022; 185: 3467-3486\nScopus (46)\nSummary\nFull Text\nFull Text PDF\n32.Cantoni C Lin Q Dorsett Y et al.\nAlterations of host–gut microbiome interactions in multiple sclerosis.\nEBioMedicine. 2022; 76103798\nScopus (43)\nSummary\nFull Text\nFull Text PDF\n33.Bäcker-Koduah P Bellmann-Strobl J Scheel M et al.\n`
│   inner_content: `s in obesity.\nAAPS J. 2017; 19: 921-930\nScopus (85)\n31.Zhou X Baumann R Gao X et al.\nGut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course.\nCell. 2022; 185: 3467-3486\nScopus (46)\nSummary\nFull Text\nFull Text PDF\n32.Cantoni C Lin Q Dorsett Y et al.\nAlterations of host–gut microbiome interactions in multiple sclerosis.\nEBioMedicine. 2022; 76103798\nScopus (43)\nSummary\nFull Text\nFull Text PDF\n33.Bäcker-Koduah P Bellmann-Strobl J Scheel M et al.\n`├── BoldNode
│   full_match: `__vitamin D__`
│   inner_content: `vitamin D`
│   children:
│   ├── TextNode
│   │   full_match: `vitamin D`
│   │   inner_content: `vitamin D`├── TextNode
│   full_match: ` and disease severity in multiple sclerosis-baseline data from the randomized controlled trial (EVIDIMS).\nFront Neurol. 2020; 11: 129\nScopus (11)\n34.Cortese M Munger KL Martínez-Lapiscina EH et al.\n`
│   inner_content: ` and disease severity in multiple sclerosis-baseline data from the randomized controlled trial (EVIDIMS).\nFront Neurol. 2020; 11: 129\nScopus (11)\n34.Cortese M Munger KL Martínez-Lapiscina EH et al.\n`├── BoldNode
│   full_match: `__vitamin D__`
│   inner_content: `vitamin D`
│   children:
│   ├── TextNode
│   │   full_match: `vitamin D`
│   │   inner_content: `vitamin D`├── TextNode
│   full_match: `, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT.\nNeurology. 2020; 94: e1950-e1960\nScopus (31)\n35.Hupperts R Smolders J Vieth R et al.\nRandomized trial of daily high-dose `
│   inner_content: `, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT.\nNeurology. 2020; 94: e1950-e1960\nScopus (31)\n35.Hupperts R Smolders J Vieth R et al.\nRandomized trial of daily high-dose `├── BoldNode
│   full_match: `__vitamin D3__`
│   inner_content: `vitamin D3`
│   children:
│   ├── TextNode
│   │   full_match: `vitamin D3`
│   │   inner_content: `vitamin D3`├── TextNode
│   full_match: ` in patients with RRMS receiving subcutaneous interferon β-1a.\nNeurology. 2019; 93: e1906-e1916\nScopus (74)\n36.Bjornevik K Cortese M Healy BC et al.\nLongitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.\nScience. 2022; 375: 296-301\nScopus (647)\n37.Tengvall K Huang J Hellström C et al.\nMolecular mimicry between anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk.\nProc Natl Acad Sci USA. 2019; 116: 16955-16960\nScopus (86)\n38.Lanz TV Brewer RC Ho PP et al.\nClonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM.\nNature. 2022; 603: 321-327\nScopus (251)\n39.Zhang N Zuo Y Jiang L Peng Y Huang X Zuo L\nEpstein-Barr virus and neurological diseases.\nFront Mol Biosci. 2022; 8816098\nScopus (40)\n40.Montgomery S Hiyoshi A Burkill S Alfredsson L Bahmanyar S Olsson T\nConcussion in adolescence and risk of multiple sclerosis.\nAnn Neurol. 2017; 82: 554-561\nScopus (37)\n41.Degelman ML Herman KM\nSmoking and multiple sclerosis: a systematic review and meta-analysis using the Bradford Hill criteria for causation.\nMult Scler Relat Disord. 2017; 17: 207-216\nScopus (91)\nSummary\nFull Text\nFull Text PDF\n42.Wu S-Y Xing F Sharma S et al.\nNicotine promotes brain metastasis by polarizing microglia and suppressing innate immune function.\nJ Exp Med. 2020; 217e20191131\nScopus (48)\n43.Oakes JM Fuchs RM Gardner JD Lazartigues E Yue X\nNicotine and the renin–angiotensin system.\nAm J Physiol Regul Integr Comp Physiol. 2018; 315: R895-R906\nScopus (199)\n44.Olsson T Barcellos LF Alfredsson L\nInteractions between genetic, lifestyle and environmental risk factors for multiple sclerosis.\nNat Rev Neurol. 2017; 13: 25-36\nScopus (636)\n45.Zhang SL Yue Z Arnold DM Artiushin G Sehgal A\nA circadian clock in the `
│   inner_content: ` in patients with RRMS receiving subcutaneous interferon β-1a.\nNeurology. 2019; 93: e1906-e1916\nScopus (74)\n36.Bjornevik K Cortese M Healy BC et al.\nLongitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.\nScience. 2022; 375: 296-301\nScopus (647)\n37.Tengvall K Huang J Hellström C et al.\nMolecular mimicry between anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk.\nProc Natl Acad Sci USA. 2019; 116: 16955-16960\nScopus (86)\n38.Lanz TV Brewer RC Ho PP et al.\nClonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM.\nNature. 2022; 603: 321-327\nScopus (251)\n39.Zhang N Zuo Y Jiang L Peng Y Huang X Zuo L\nEpstein-Barr virus and neurological diseases.\nFront Mol Biosci. 2022; 8816098\nScopus (40)\n40.Montgomery S Hiyoshi A Burkill S Alfredsson L Bahmanyar S Olsson T\nConcussion in adolescence and risk of multiple sclerosis.\nAnn Neurol. 2017; 82: 554-561\nScopus (37)\n41.Degelman ML Herman KM\nSmoking and multiple sclerosis: a systematic review and meta-analysis using the Bradford Hill criteria for causation.\nMult Scler Relat Disord. 2017; 17: 207-216\nScopus (91)\nSummary\nFull Text\nFull Text PDF\n42.Wu S-Y Xing F Sharma S et al.\nNicotine promotes brain metastasis by polarizing microglia and suppressing innate immune function.\nJ Exp Med. 2020; 217e20191131\nScopus (48)\n43.Oakes JM Fuchs RM Gardner JD Lazartigues E Yue X\nNicotine and the renin–angiotensin system.\nAm J Physiol Regul Integr Comp Physiol. 2018; 315: R895-R906\nScopus (199)\n44.Olsson T Barcellos LF Alfredsson L\nInteractions between genetic, lifestyle and environmental risk factors for multiple sclerosis.\nNat Rev Neurol. 2017; 13: 25-36\nScopus (636)\n45.Zhang SL Yue Z Arnold DM Artiushin G Sehgal A\nA circadian clock in the `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: ` regulates xenobiotic efflux.\nCell. 2018; 173: 130-139.e10\nScopus (131)\nSummary\nFull Text\nFull Text PDF\n46.Cuddapah VA Zhang SL Sehgal A\nRegulation of the `
│   inner_content: ` regulates xenobiotic efflux.\nCell. 2018; 173: 130-139.e10\nScopus (131)\nSummary\nFull Text\nFull Text PDF\n46.Cuddapah VA Zhang SL Sehgal A\nRegulation of the `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: ` by circadian rhythms and sleep.\nTrends Neurosci. 2019; 42: 500-510\nScopus (99)\nSummary\nFull Text\nFull Text PDF\n47.Artiushin G Zhang SL Tricoire H Sehgal A\nEndocytosis at the Drosophila `
│   inner_content: ` by circadian rhythms and sleep.\nTrends Neurosci. 2019; 42: 500-510\nScopus (99)\nSummary\nFull Text\nFull Text PDF\n47.Artiushin G Zhang SL Tricoire H Sehgal A\nEndocytosis at the Drosophila `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: ` as a function for sleep.\neLife. 2018; 7e43326\nScopus (49)\n48.Sun J Wu J Hua F Chen Y Zhan F Xu G\nSleep deprivation induces cognitive impairment by increasing `
│   inner_content: ` as a function for sleep.\neLife. 2018; 7e43326\nScopus (49)\n48.Sun J Wu J Hua F Chen Y Zhan F Xu G\nSleep deprivation induces cognitive impairment by increasing `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: ` permeability via CD44.\nFront Neurol. 2020; 11563916\nScopus (22)\n49.Nishihara H Perriot S Gastfriend BD et al.\nIntrinsic `
│   inner_content: ` permeability via CD44.\nFront Neurol. 2020; 11563916\nScopus (22)\n49.Nishihara H Perriot S Gastfriend BD et al.\nIntrinsic `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: ` dysfunction contributes to multiple sclerosis pathogenesis.\nBrain. 2022; 145: 4334-4348\nScopus (24)\n50.Filippi M Brück W Chard D et al.\nAssociation between pathological and MRI findings in multiple sclerosis.\nLancet Neurol. 2019; 18: 198-210\nScopus (144)\nSummary\nFull Text\nFull Text PDF\n51.Yong HYF Yong VW\nMechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis.\nNat Rev Neurol. 2022; 18: 40-55\nScopus (40)\n52.Petersen MA Ryu JK Akassoglou K\nFibrinogen in neurological diseases: mechanisms, imaging and therapeutics.\nNat Rev Neurosci. 2018; 19: 283-301\nScopus (256)\n53.Yates RL Esiri MM Palace J Jacobs B Perera R DeLuca GC\nFibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex.\nAnn Neurol. 2017; 82: 259-270\nScopus (77)\n54.Ryu JK Rafalski VA Meyer-Franke A et al.\nFibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration.\nNat Immunol. 2018; 19: 1212-1223\nScopus (118)\n55.Willis CM Nicaise AM Menoret A et al.\nExtracellular vesicle fibrinogen induces encephalitogenic CD8+ T cells in a mouse model of multiple sclerosis.\nProc Natl Acad Sci USA. 2019; 116: 10488-10493\nScopus (30)\n56.Brailoiu E Shipsky MM Yan G Abood ME Brailoiu GC\nMechanisms of modulation of brain microvascular endothelial cells function by thrombin.\nBrain Res. 2017; 1657: 167-175\nScopus (40)\n57.Suthiphosuwan S Sati P Absinta M et al.\nParamagnetic rim sign in radiologically isolated syndrome.\nJAMA Neurol. 2020; 77: 653-655\nScopus (32)\n58.Hagemeier J Ramanathan M Schweser F et al.\nIron-related gene variants and brain iron in multiple sclerosis and healthy individuals.\nNeuroimage Clin. 2017; 17: 530-540\nScopus (27)\n59.Sweeney MD Zhao Z Montagne A Nelson AR Zlokovic BV\n`
│   inner_content: ` dysfunction contributes to multiple sclerosis pathogenesis.\nBrain. 2022; 145: 4334-4348\nScopus (24)\n50.Filippi M Brück W Chard D et al.\nAssociation between pathological and MRI findings in multiple sclerosis.\nLancet Neurol. 2019; 18: 198-210\nScopus (144)\nSummary\nFull Text\nFull Text PDF\n51.Yong HYF Yong VW\nMechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis.\nNat Rev Neurol. 2022; 18: 40-55\nScopus (40)\n52.Petersen MA Ryu JK Akassoglou K\nFibrinogen in neurological diseases: mechanisms, imaging and therapeutics.\nNat Rev Neurosci. 2018; 19: 283-301\nScopus (256)\n53.Yates RL Esiri MM Palace J Jacobs B Perera R DeLuca GC\nFibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex.\nAnn Neurol. 2017; 82: 259-270\nScopus (77)\n54.Ryu JK Rafalski VA Meyer-Franke A et al.\nFibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration.\nNat Immunol. 2018; 19: 1212-1223\nScopus (118)\n55.Willis CM Nicaise AM Menoret A et al.\nExtracellular vesicle fibrinogen induces encephalitogenic CD8+ T cells in a mouse model of multiple sclerosis.\nProc Natl Acad Sci USA. 2019; 116: 10488-10493\nScopus (30)\n56.Brailoiu E Shipsky MM Yan G Abood ME Brailoiu GC\nMechanisms of modulation of brain microvascular endothelial cells function by thrombin.\nBrain Res. 2017; 1657: 167-175\nScopus (40)\n57.Suthiphosuwan S Sati P Absinta M et al.\nParamagnetic rim sign in radiologically isolated syndrome.\nJAMA Neurol. 2020; 77: 653-655\nScopus (32)\n58.Hagemeier J Ramanathan M Schweser F et al.\nIron-related gene variants and brain iron in multiple sclerosis and healthy individuals.\nNeuroimage Clin. 2017; 17: 530-540\nScopus (27)\n59.Sweeney MD Zhao Z Montagne A Nelson AR Zlokovic BV\n`├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: `: from physiology to disease and back.\nPhysiol Rev. 2019; 99: 21-78\nScopus (1043)\n60.Benedict RHB Amato MP DeLuca J Geurts JJG\nCognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues.\nLancet Neurol. 2020; 19: 860-871\nScopus (237)\nSummary\nFull Text\nFull Text PDF\n61.Granziera C Wuerfel J Barkhof F et al.\nQuantitative magnetic resonance imaging towards clinical application in multiple sclerosis.\nBrain. 2021; 144: 1296-1311\nScopus (58)\n62.Sivakolundu DK West KL Maruthy GB et al.\nReduced arterial compliance along the cerebrovascular tree predicts cognitive slowing in multiple sclerosis: Evidence for a neurovascular uncoupling hypothesis.\nMult Scler. 2020; 26: 1486-1496\nScopus (13)\n63.Barro C Benkert P Disanto G et al.\nSerum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.\nBrain. 2018; 141: 2382-2391\nScopus (300)\n64.Uher T McComb M Galkin S et al.\nNeurofilament levels are associated with `
│   inner_content: `: from physiology to disease and back.\nPhysiol Rev. 2019; 99: 21-78\nScopus (1043)\n60.Benedict RHB Amato MP DeLuca J Geurts JJG\nCognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues.\nLancet Neurol. 2020; 19: 860-871\nScopus (237)\nSummary\nFull Text\nFull Text PDF\n61.Granziera C Wuerfel J Barkhof F et al.\nQuantitative magnetic resonance imaging towards clinical application in multiple sclerosis.\nBrain. 2021; 144: 1296-1311\nScopus (58)\n62.Sivakolundu DK West KL Maruthy GB et al.\nReduced arterial compliance along the cerebrovascular tree predicts cognitive slowing in multiple sclerosis: Evidence for a neurovascular uncoupling hypothesis.\nMult Scler. 2020; 26: 1486-1496\nScopus (13)\n63.Barro C Benkert P Disanto G et al.\nSerum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.\nBrain. 2018; 141: 2382-2391\nScopus (300)\n64.Uher T McComb M Galkin S et al.\nNeurofilament levels are associated with `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: ` integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis.\nMult Scler. 2021; 27: 220-231\nScopus (41)\n65.Sejbaek T Nielsen HH Penner N et al.\nDimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients.\nJ Neurol Neurosurg Psychiatry. 2019; 90: 1324-1330\n66.Kuhle J Plavina T Barro C et al.\nNeurofilament light levels are associated with long-term outcomes in multiple sclerosis.\nMult Scler. 2020; 26: 1691-1699\nScopus (57)\n67.Hyun J-W Kim Y Kim G Kim S-H Kim HJ\nLongitudinal analysis of serum neurofilament light chain: a potential therapeutic monitoring biomarker for multiple sclerosis.\nMult Scler. 2020; 26: 659-667\nScopus (21)\n68.Sandelius Å Zetterberg H Blennow K et al.\nPlasma neurofilament light chain concentration in the inherited peripheral neuropathies.\nNeurology. 2018; 90: e518-e524\nScopus (162)\n69.Kalm M Boström M Sandelius Å et al.\nSerum concentrations of the axonal injury marker neurofilament light protein are not influenced by `
│   inner_content: ` integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis.\nMult Scler. 2021; 27: 220-231\nScopus (41)\n65.Sejbaek T Nielsen HH Penner N et al.\nDimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients.\nJ Neurol Neurosurg Psychiatry. 2019; 90: 1324-1330\n66.Kuhle J Plavina T Barro C et al.\nNeurofilament light levels are associated with long-term outcomes in multiple sclerosis.\nMult Scler. 2020; 26: 1691-1699\nScopus (57)\n67.Hyun J-W Kim Y Kim G Kim S-H Kim HJ\nLongitudinal analysis of serum neurofilament light chain: a potential therapeutic monitoring biomarker for multiple sclerosis.\nMult Scler. 2020; 26: 659-667\nScopus (21)\n68.Sandelius Å Zetterberg H Blennow K et al.\nPlasma neurofilament light chain concentration in the inherited peripheral neuropathies.\nNeurology. 2018; 90: e518-e524\nScopus (162)\n69.Kalm M Boström M Sandelius Å et al.\nSerum concentrations of the axonal injury marker neurofilament light protein are not influenced by `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: ` permeability.\nBrain Res. 2017; 1668: 12-19\nScopus (44)\n70.Watanabe M Nakamura Y Michalak Z et al.\nSerum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.\nNeurology. 2019; 93: e1299-e1311\nScopus (112)\n71.Papa L Ladde JG O&#39;Brien JF et al.\nEvaluation of glial and neuronal blood biomarkers compared with clinical decision rules in assessing the need for computed tomography in patients with mild traumatic brain injury.\nJAMA Netw Open. 2022; 5e221302\nScopus (14)\n72.Brambilla R\nThe contribution of astrocytes to the neuroinflammatory response in multiple sclerosis and experimental autoimmune encephalomyelitis.\nActa Neuropathol. 2019; 137: 757-783\nScopus (139)\n73.Martinsen V Kursula P\nMultiple sclerosis and myelin basic protein: insights into protein disorder and disease.\nAmino Acids. 2022; 54: 99-109\nScopus (42)\n74.Nohejlova H Kayserova J Capek V Toman T Krsek P Liba Z\nPaediatric onset of multiple sclerosis: analysis of chemokine and cytokine levels in the context of the early clinical course.\nMult Scler Relat Disord. 2020; 46102467\nScopus (5)\nSummary\nFull Text\nFull Text PDF\n75.Wang D Duan H Feng J et al.\nSoluble CD146, a cerebrospinal fluid marker for neuroinflammation, promotes `
│   inner_content: ` permeability.\nBrain Res. 2017; 1668: 12-19\nScopus (44)\n70.Watanabe M Nakamura Y Michalak Z et al.\nSerum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.\nNeurology. 2019; 93: e1299-e1311\nScopus (112)\n71.Papa L Ladde JG O&#39;Brien JF et al.\nEvaluation of glial and neuronal blood biomarkers compared with clinical decision rules in assessing the need for computed tomography in patients with mild traumatic brain injury.\nJAMA Netw Open. 2022; 5e221302\nScopus (14)\n72.Brambilla R\nThe contribution of astrocytes to the neuroinflammatory response in multiple sclerosis and experimental autoimmune encephalomyelitis.\nActa Neuropathol. 2019; 137: 757-783\nScopus (139)\n73.Martinsen V Kursula P\nMultiple sclerosis and myelin basic protein: insights into protein disorder and disease.\nAmino Acids. 2022; 54: 99-109\nScopus (42)\n74.Nohejlova H Kayserova J Capek V Toman T Krsek P Liba Z\nPaediatric onset of multiple sclerosis: analysis of chemokine and cytokine levels in the context of the early clinical course.\nMult Scler Relat Disord. 2020; 46102467\nScopus (5)\nSummary\nFull Text\nFull Text PDF\n75.Wang D Duan H Feng J et al.\nSoluble CD146, a cerebrospinal fluid marker for neuroinflammation, promotes `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: ` dysfunction.\nTheranostics. 2020; 10: 231-246\nScopus (21)\n76.Ziliotto N Lamberti N Manfredini F et al.\nBaseline and overtime variations of soluble adhesion molecule plasma concentrations are associated with mobility recovery after rehabilitation in multiple sclerosis patients.\nJ Neuroimmunol. 2021; 352577473\nScopus (2)\nSummary\nFull Text\nFull Text PDF\n77.Fournier AP Quenault A Martinez de Lizarrondo S et al.\nPrediction of disease activity in models of multiple sclerosis by molecular magnetic resonance imaging of P-selectin.\nProc Natl Acad Sci USA. 2017; 114: 6116-6121\nScopus (37)\n78.Masuda H Mori M Uchida T Uzawa A Ohtani R Kuwabara S\nSoluble CD40 ligand contributes to `
│   inner_content: ` dysfunction.\nTheranostics. 2020; 10: 231-246\nScopus (21)\n76.Ziliotto N Lamberti N Manfredini F et al.\nBaseline and overtime variations of soluble adhesion molecule plasma concentrations are associated with mobility recovery after rehabilitation in multiple sclerosis patients.\nJ Neuroimmunol. 2021; 352577473\nScopus (2)\nSummary\nFull Text\nFull Text PDF\n77.Fournier AP Quenault A Martinez de Lizarrondo S et al.\nPrediction of disease activity in models of multiple sclerosis by molecular magnetic resonance imaging of P-selectin.\nProc Natl Acad Sci USA. 2017; 114: 6116-6121\nScopus (37)\n78.Masuda H Mori M Uchida T Uzawa A Ohtani R Kuwabara S\nSoluble CD40 ligand contributes to `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: ` breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder.\nJ Neuroimmunol. 2017; 305: 102-107\nScopus (32)\nSummary\nFull Text\nFull Text PDF\n79.Agah E Zardoui A Saghazadeh A Ahmadi M Tafakhori A Rezaei N\nOsteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: a systematic review and meta-analysis.\nPLoS One. 2018; 13e0190252\nScopus (52)\n80.Spitzer D Puetz T Armbrust M et al.\nAnti-osteopontin therapy leads to improved edema and infarct size in a murine model of ischemic stroke.\nSci Rep. 2022; 1220925\nScopus (2)\n81.Clemente N Comi C Raineri D et al.\nRole of anti-osteopontin antibodies in multiple sclerosis and experimental autoimmune encephalomyelitis.\nFront Immunol. 2017; 8: 321\nScopus (29)\n82.Çiçekli E Sayan S Kotan D\nAvailability of fibrinogen/albumin ratio in MS attack.\nMult Scler Relat Disord. 2022; 60103674\nScopus (4)\nSummary\nFull Text\nFull Text PDF\n83.Miranda Acuña J Hidalgo de la Cruz M Ros AL Tapia SP Martínez Ginés ML de Andrés Frutos CD\nElevated plasma fibrinogen levels in multiple sclerosis patients during relapse.\nMult Scler Relat Disord. 2017; 18: 157-160\nScopus (17)\nSummary\nFull Text\nFull Text PDF\n84.Schaller-Paule MA Yalachkov Y Steinmetz H et al.\nAnalysis of CSF D-dimer to identify intrathecal fibrin-driven autoimmunity in patients with multiple sclerosis.\nNeurol Neuroimmunol Neuroinflamm. 2022; 9e1150\nScopus (5)\n85.Balasa R Barcutean L Mosora O Manu D\nReviewing the significance of `
│   inner_content: ` breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder.\nJ Neuroimmunol. 2017; 305: 102-107\nScopus (32)\nSummary\nFull Text\nFull Text PDF\n79.Agah E Zardoui A Saghazadeh A Ahmadi M Tafakhori A Rezaei N\nOsteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: a systematic review and meta-analysis.\nPLoS One. 2018; 13e0190252\nScopus (52)\n80.Spitzer D Puetz T Armbrust M et al.\nAnti-osteopontin therapy leads to improved edema and infarct size in a murine model of ischemic stroke.\nSci Rep. 2022; 1220925\nScopus (2)\n81.Clemente N Comi C Raineri D et al.\nRole of anti-osteopontin antibodies in multiple sclerosis and experimental autoimmune encephalomyelitis.\nFront Immunol. 2017; 8: 321\nScopus (29)\n82.Çiçekli E Sayan S Kotan D\nAvailability of fibrinogen/albumin ratio in MS attack.\nMult Scler Relat Disord. 2022; 60103674\nScopus (4)\nSummary\nFull Text\nFull Text PDF\n83.Miranda Acuña J Hidalgo de la Cruz M Ros AL Tapia SP Martínez Ginés ML de Andrés Frutos CD\nElevated plasma fibrinogen levels in multiple sclerosis patients during relapse.\nMult Scler Relat Disord. 2017; 18: 157-160\nScopus (17)\nSummary\nFull Text\nFull Text PDF\n84.Schaller-Paule MA Yalachkov Y Steinmetz H et al.\nAnalysis of CSF D-dimer to identify intrathecal fibrin-driven autoimmunity in patients with multiple sclerosis.\nNeurol Neuroimmunol Neuroinflamm. 2022; 9e1150\nScopus (5)\n85.Balasa R Barcutean L Mosora O Manu D\nReviewing the significance of `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: ` disruption in multiple sclerosis pathology and treatment.\nInt J Mol Sci. 2021; 228370\nScopus (40)\n86.Pyka-Fosciak G Lis GJ Litwin JA\nEffect of natalizumab treatment on metalloproteinases and their inhibitors in a mouse model of multiple sclerosis.\nJ Physiol Pharmacol. 2020; 71: 265-273\n87.Knudsen MH Lindberg U Frederiksen JL et al.\n`
│   inner_content: ` disruption in multiple sclerosis pathology and treatment.\nInt J Mol Sci. 2021; 228370\nScopus (40)\n86.Pyka-Fosciak G Lis GJ Litwin JA\nEffect of natalizumab treatment on metalloproteinases and their inhibitors in a mouse model of multiple sclerosis.\nJ Physiol Pharmacol. 2020; 71: 265-273\n87.Knudsen MH Lindberg U Frederiksen JL et al.\n`├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: ` permeability changes in the first year after alemtuzumab treatment predict 2-year outcomes in relapsing-remitting multiple sclerosis.\nMult Scler Relat Disord. 2022; 63103891\nScopus (5)\nSummary\nFull Text\nFull Text PDF\n88.Nguyen K Juillard P Hawke S Grau GE Marsh-Wakefield F\nTrans-endothelial migration of memory T Cells is impaired in alemtuzumab-treated multiple sclerosis patients.\nJ Clin Med. 2022; 116266\nScopus (1)\n89.Ford RK Juillard P Hawke S Grau GE Marsh-Wakefield F\nCladribine reduces trans-endothelial migration of memory T cells across an in vitro `
│   inner_content: ` permeability changes in the first year after alemtuzumab treatment predict 2-year outcomes in relapsing-remitting multiple sclerosis.\nMult Scler Relat Disord. 2022; 63103891\nScopus (5)\nSummary\nFull Text\nFull Text PDF\n88.Nguyen K Juillard P Hawke S Grau GE Marsh-Wakefield F\nTrans-endothelial migration of memory T Cells is impaired in alemtuzumab-treated multiple sclerosis patients.\nJ Clin Med. 2022; 116266\nScopus (1)\n89.Ford RK Juillard P Hawke S Grau GE Marsh-Wakefield F\nCladribine reduces trans-endothelial migration of memory T cells across an in vitro `├── BoldNode
│   full_match: `__blood–brain barrier__`
│   inner_content: `blood–brain barrier`
│   children:
│   ├── TextNode
│   │   full_match: `blood–brain barrier`
│   │   inner_content: `blood–brain barrier`├── TextNode
│   full_match: `.\nJ Clin Med. 2022; 116006\nScopus (4)\n90.Sellebjerg F Blinkenberg M Sorensen PS\nAnti-CD20 monoclonal antibodies for relapsing and progressive multiple sclerosis.\nCNS Drugs. 2020; 34: 269-280\nScopus (42)\n91.Krämer J Bar-Or A Turner TJ Wiendl H\nBruton tyrosine kinase inhibitors for multiple sclerosis.\nNat Rev Neurol. 2023; 19: 289-304\nScopus (9)\n92.Banoth B Cassel SL\nBruton tyrosine kinase inhibition: clinical relevance beyond B cells.\nJ Allergy Clin Immunol. 2017; 140: 985-987\nScopus (8)\nSummary\nFull Text\nFull Text PDF\n93.Mizuno M Noto D Kaga N Chiba A Miyake S\nThe dual role of short fatty acid chains in the pathogenesis of autoimmune disease models.\nPLoS One. 2017; 12e0173032\nScopus (149)\n94.Dai Y Wei T Shen Z Bei Y Lin H Dai H\nClassical HDACs in the regulation of neuroinflammation.\nNeurochem Int. 2021; 150105182\nScopus (16)\n95.Shen Y Yang R Zhao J et al.\nThe histone deacetylase inhibitor belinostat ameliorates experimental autoimmune encephalomyelitis in mice by inhibiting TLR2/MyD88 and HDAC3/NF-κB p65-mediated neuroinflammation.\nPharmacol Res. 2022; 176105969\nScopus (15)\n96.Buonvicino D Ranieri G Chiarugi A\nTreatment with non-specific HDAC inhibitors administered after disease onset does not delay evolution in a mouse model of progressive multiple sclerosis.\nNeuroscience. 2021; 465: 38-45\nScopus (6)\nSummary\nFull Text\nFull Text PDF\n97.Ghaiad HR Nooh MM El-Sawalhi MM Shaheen AA\nResveratrol promotes remyelination in cuprizone model of multiple sclerosis: biochemical and histological study.\nMol Neurobiol. 2017; 54: 3219-3229\nScopus (85)\n98.Boffa G Lapucci C Sbragia E et al.\nAggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab.\nEur J Neurol. 2020; 27: 2047-2055\nScopus (13)\n99.Roudi S Rädler JA El Andaloussi S\nTherapeutic potential of extracellular vesicles in neurodegenerative disorders.\nHandb Clin Neurol. 2023; 193: 243-266\nScopus (0)\n100.Hayakawa K Chan SJ Mandeville ET et al.\nProtective effects of endothelial progenitor cell-derived extracellular mitochondria in brain endothelium.\nStem Cells. 2018; 36: 1404-1410\nScopus (91)\n101.Charabati M Rabanel J-M Ramassamy C Prat A\nOvercoming the brain barriers: from immune cells to nanoparticles.\nTrends Pharmacol Sci. 2020; 41: 42-54\nScopus (27)`
│   inner_content: `.\nJ Clin Med. 2022; 116006\nScopus (4)\n90.Sellebjerg F Blinkenberg M Sorensen PS\nAnti-CD20 monoclonal antibodies for relapsing and progressive multiple sclerosis.\nCNS Drugs. 2020; 34: 269-280\nScopus (42)\n91.Krämer J Bar-Or A Turner TJ Wiendl H\nBruton tyrosine kinase inhibitors for multiple sclerosis.\nNat Rev Neurol. 2023; 19: 289-304\nScopus (9)\n92.Banoth B Cassel SL\nBruton tyrosine kinase inhibition: clinical relevance beyond B cells.\nJ Allergy Clin Immunol. 2017; 140: 985-987\nScopus (8)\nSummary\nFull Text\nFull Text PDF\n93.Mizuno M Noto D Kaga N Chiba A Miyake S\nThe dual role of short fatty acid chains in the pathogenesis of autoimmune disease models.\nPLoS One. 2017; 12e0173032\nScopus (149)\n94.Dai Y Wei T Shen Z Bei Y Lin H Dai H\nClassical HDACs in the regulation of neuroinflammation.\nNeurochem Int. 2021; 150105182\nScopus (16)\n95.Shen Y Yang R Zhao J et al.\nThe histone deacetylase inhibitor belinostat ameliorates experimental autoimmune encephalomyelitis in mice by inhibiting TLR2/MyD88 and HDAC3/NF-κB p65-mediated neuroinflammation.\nPharmacol Res. 2022; 176105969\nScopus (15)\n96.Buonvicino D Ranieri G Chiarugi A\nTreatment with non-specific HDAC inhibitors administered after disease onset does not delay evolution in a mouse model of progressive multiple sclerosis.\nNeuroscience. 2021; 465: 38-45\nScopus (6)\nSummary\nFull Text\nFull Text PDF\n97.Ghaiad HR Nooh MM El-Sawalhi MM Shaheen AA\nResveratrol promotes remyelination in cuprizone model of multiple sclerosis: biochemical and histological study.\nMol Neurobiol. 2017; 54: 3219-3229\nScopus (85)\n98.Boffa G Lapucci C Sbragia E et al.\nAggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab.\nEur J Neurol. 2020; 27: 2047-2055\nScopus (13)\n99.Roudi S Rädler JA El Andaloussi S\nTherapeutic potential of extracellular vesicles in neurodegenerative disorders.\nHandb Clin Neurol. 2023; 193: 243-266\nScopus (0)\n100.Hayakawa K Chan SJ Mandeville ET et al.\nProtective effects of endothelial progenitor cell-derived extracellular mitochondria in brain endothelium.\nStem Cells. 2018; 36: 1404-1410\nScopus (91)\n101.Charabati M Rabanel J-M Ramassamy C Prat A\nOvercoming the brain barriers: from immune cells to nanoparticles.\nTrends Pharmacol Sci. 2020; 41: 42-54\nScopus (27)`├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!28,000 hits for &quot;blood brain barrier&quot; &quot;vitamin d&quot; in Google Scholar`
│   inner_content: `28,000 hits for &quot;blood brain barrier&quot; &quot;vitamin d&quot; in Google Scholar`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `28,000 hits for &quot;blood brain barrier&quot; &quot;vitamin d&quot; in Google Scholar`
│   │   inner_content: `28,000 hits for &quot;blood brain barrier&quot; &quot;vitamin d&quot; in Google Scholar`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── BoldNode
│   full_match: `__https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C48&amp;q=%22blood+brain+barrier%22+%22vitamin+d%22&amp;btnG=|Google Scholar]__`
│   inner_content: `https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C48&amp;q=%22blood+brain+barrier%22+%22vitamin+d%22&amp;btnG=|Google Scholar]`
│   children:
│   ├── TextNode
│   │   full_match: `https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C48&amp;q=%22blood+brain+barrier%22+%22vitamin+d%22&amp;btnG=|Google Scholar]`
│   │   inner_content: `https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C48&amp;q=%22blood+brain+barrier%22+%22vitamin+d%22&amp;btnG=|Google Scholar]`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── ListItemNode
│   full_match: `*Active form of vitamin D directly protects the blood–brain barrier in multiple sclerosis-  August 2017 https://doi.org/10.1111/cen3.12398  FREE PDF`
│   inner_content: `Active form of vitamin D directly protects the blood–brain barrier in multiple sclerosis-  August 2017 https://doi.org/10.1111/cen3.12398  FREE PDF`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Active form of vitamin D directly protects the blood–brain barrier in multiple sclerosis-  August 2017 https://doi.org/10.1111/cen3.12398  FREE PDF`
│   │   inner_content: `Active form of vitamin D directly protects the blood–brain barrier in multiple sclerosis-  August 2017 https://doi.org/10.1111/cen3.12398  FREE PDF`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── ListItemNode
│   full_match: `*Full spectrum of vitamin D immunomodulation in multiple sclerosis: mechanisms and therapeutic implications - June 2022  https://doi.org/10.1093/braincomms/fcac171 FREE PDF`
│   inner_content: `Full spectrum of vitamin D immunomodulation in multiple sclerosis: mechanisms and therapeutic implications - June 2022  https://doi.org/10.1093/braincomms/fcac171 FREE PDF`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Full spectrum of vitamin D immunomodulation in multiple sclerosis: mechanisms and therapeutic implications - June 2022  https://doi.org/10.1093/braincomms/fcac171 FREE PDF`
│   │   inner_content: `Full spectrum of vitamin D immunomodulation in multiple sclerosis: mechanisms and therapeutic implications - June 2022  https://doi.org/10.1093/braincomms/fcac171 FREE PDF`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── ListItemNode
│   full_match: `**&quot;In this review, we focus on recent published data describing the biological effects of Vitamin D in animal models of multiple sclerosis on immune cells, blood–brain barrier function, activation of glial cells and its potential neuroprotective effects.&quot;`
│   inner_content: `&quot;In this review, we focus on recent published data describing the biological effects of Vitamin D in animal models of multiple sclerosis on immune cells, blood–brain barrier function, activation of glial cells and its potential neuroprotective effects.&quot;`
│   depth: `2`
│   children:
│   ├── TextNode
│   │   full_match: `&quot;In this review, we focus on recent published data describing the biological effects of Vitamin D in animal models of multiple sclerosis on immune cells, blood–brain barrier function, activation of glial cells and its potential neuroprotective effects.&quot;`
│   │   inner_content: `&quot;In this review, we focus on recent published data describing the biological effects of Vitamin D in animal models of multiple sclerosis on immune cells, blood–brain barrier function, activation of glial cells and its potential neuroprotective effects.&quot;`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── ListItemNode
│   full_match: `*The Role of Vitamin D in Neuroprotection in Multiple Sclerosis: An Update - June 2023  https://doi.org/10.3390/nu15132978 FREE PDF`
│   inner_content: `The Role of Vitamin D in Neuroprotection in Multiple Sclerosis: An Update - June 2023  https://doi.org/10.3390/nu15132978 FREE PDF`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `The Role of Vitamin D in Neuroprotection in Multiple Sclerosis: An Update - June 2023  https://doi.org/10.3390/nu15132978 FREE PDF`
│   │   inner_content: `The Role of Vitamin D in Neuroprotection in Multiple Sclerosis: An Update - June 2023  https://doi.org/10.3390/nu15132978 FREE PDF`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── ListItemNode
│   full_match: `*Intranasal administration of vitamin D attenuates blood–brain barrier disruption through endogenous upregulation of osteopontin and activation of CD44/P-gp glycosylation signaling after subarachnoid hemorrhage in rats - Oct 2016 https://doi.org/10.1177/0271678X16671147 FREE PDF`
│   inner_content: `Intranasal administration of vitamin D attenuates blood–brain barrier disruption through endogenous upregulation of osteopontin and activation of CD44/P-gp glycosylation signaling after subarachnoid hemorrhage in rats - Oct 2016 https://doi.org/10.1177/0271678X16671147 FREE PDF`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Intranasal administration of vitamin D attenuates blood–brain barrier disruption through endogenous upregulation of osteopontin and activation of CD44/P-gp glycosylation signaling after subarachnoid hemorrhage in rats - Oct 2016 https://doi.org/10.1177/0271678X16671147 FREE PDF`
│   │   inner_content: `Intranasal administration of vitamin D attenuates blood–brain barrier disruption through endogenous upregulation of osteopontin and activation of CD44/P-gp glycosylation signaling after subarachnoid hemorrhage in rats - Oct 2016 https://doi.org/10.1177/0271678X16671147 FREE PDF`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── ListItemNode
│   full_match: `**Note: VitaminDWiki has been successfully experimenting in inhaing Vitamin D since about 2015`
│   inner_content: `Note: VitaminDWiki has been successfully experimenting in inhaing Vitamin D since about 2015`
│   depth: `2`
│   children:
│   ├── TextNode
│   │   full_match: `Note: VitaminDWiki has been successfully experimenting in inhaing Vitamin D since about 2015`
│   │   inner_content: `Note: VitaminDWiki has been successfully experimenting in inhaing Vitamin D since about 2015`├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!VitaminDWiki – ((Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019))`
│   inner_content: `VitaminDWiki – ((Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019))`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `VitaminDWiki – `
│   │   inner_content: `VitaminDWiki – `
│   ├── LocalLinkNode
│   │   full_match: `((Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019))`
│   │   inner_content: `Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019`
│   │   page: `Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019`
│   │   │   inner_content: `Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── IncludeNode
│   full_match: `{include page=&quot;Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}`
│   inner_content: ``
│   attrs_dict:
│   │   raw_content:  page=&quot;Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;
│   │   page: Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019
│   │   start: ~tc~ start ~/tc~
│   │   stop: ~tc~ end ~/tc~
│   children:
│   ├── TextNode
│   │   full_match: ``
│   │   inner_content: ``├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!See Brain in VitaminDWiki `
│   inner_content: `See Brain in VitaminDWiki`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `See Brain in VitaminDWiki`
│   │   inner_content: `See Brain in VitaminDWiki`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── ListItemNode
│   full_match: `*((Brain and Vitamin D - many studies))`
│   inner_content: `((Brain and Vitamin D - many studies))`
│   depth: `1`
│   children:
│   ├── LocalLinkNode
│   │   full_match: `((Brain and Vitamin D - many studies))`
│   │   inner_content: `Brain and Vitamin D - many studies`
│   │   page: `Brain and Vitamin D - many studies`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Brain and Vitamin D - many studies`
│   │   │   inner_content: `Brain and Vitamin D - many studies`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── ListItemNode
│   full_match: `*((Global burden of brain disorders surpasses cardiovascular disease and cancer - July 2023))`
│   inner_content: `((Global burden of brain disorders surpasses cardiovascular disease and cancer - July 2023))`
│   depth: `1`
│   children:
│   ├── LocalLinkNode
│   │   full_match: `((Global burden of brain disorders surpasses cardiovascular disease and cancer - July 2023))`
│   │   inner_content: `Global burden of brain disorders surpasses cardiovascular disease and cancer - July 2023`
│   │   page: `Global burden of brain disorders surpasses cardiovascular disease and cancer - July 2023`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Global burden of brain disorders surpasses cardiovascular disease and cancer - July 2023`
│   │   │   inner_content: `Global burden of brain disorders surpasses cardiovascular disease and cancer - July 2023`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── ListItemNode
│   full_match: `**Contains: Vitamin D inhaled thru the nose gets some directly to the brain`
│   inner_content: `Contains: Vitamin D inhaled thru the nose gets some directly to the brain`
│   depth: `2`
│   children:
│   ├── TextNode
│   │   full_match: `Contains: Vitamin D inhaled thru the nose gets some directly to the brain`
│   │   inner_content: `Contains: Vitamin D inhaled thru the nose gets some directly to the brain`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── ListItemNode
│   full_match: `*((Vitamin D3 Attenuates Blood-Brain Barrier Disruption due to TBI (in rats) – Feb 2021))`
│   inner_content: `((Vitamin D3 Attenuates Blood-Brain Barrier Disruption due to TBI (in rats) – Feb 2021))`
│   depth: `1`
│   children:
│   ├── LocalLinkNode
│   │   full_match: `((Vitamin D3 Attenuates Blood-Brain Barrier Disruption due to TBI (in rats) – Feb 2021))`
│   │   inner_content: `Vitamin D3 Attenuates Blood-Brain Barrier Disruption due to TBI (in rats) – Feb 2021`
│   │   page: `Vitamin D3 Attenuates Blood-Brain Barrier Disruption due to TBI (in rats) – Feb 2021`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Vitamin D3 Attenuates Blood-Brain Barrier Disruption due to TBI (in rats) – Feb 2021`
│   │   │   inner_content: `Vitamin D3 Attenuates Blood-Brain Barrier Disruption due to TBI (in rats) – Feb 2021`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── ListItemNode
│   full_match: `*((Many Neurological Diseases fought by Vitamin D - Dec 2022))`
│   inner_content: `((Many Neurological Diseases fought by Vitamin D - Dec 2022))`
│   depth: `1`
│   children:
│   ├── LocalLinkNode
│   │   full_match: `((Many Neurological Diseases fought by Vitamin D - Dec 2022))`
│   │   inner_content: `Many Neurological Diseases fought by Vitamin D - Dec 2022`
│   │   page: `Many Neurological Diseases fought by Vitamin D - Dec 2022`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Many Neurological Diseases fought by Vitamin D - Dec 2022`
│   │   │   inner_content: `Many Neurological Diseases fought by Vitamin D - Dec 2022`├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!See also in VitaminDWiki `
│   inner_content: `See also in VitaminDWiki`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `See also in VitaminDWiki`
│   │   inner_content: `See also in VitaminDWiki`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── ListItemNode
│   full_match: `*((Multiple Sclerosis risk factors - Vitamin D was the only one you can easily change - Sept 2023))`
│   inner_content: `((Multiple Sclerosis risk factors - Vitamin D was the only one you can easily change - Sept 2023))`
│   depth: `1`
│   children:
│   ├── LocalLinkNode
│   │   full_match: `((Multiple Sclerosis risk factors - Vitamin D was the only one you can easily change - Sept 2023))`
│   │   inner_content: `Multiple Sclerosis risk factors - Vitamin D was the only one you can easily change - Sept 2023`
│   │   page: `Multiple Sclerosis risk factors - Vitamin D was the only one you can easily change - Sept 2023`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Multiple Sclerosis risk factors - Vitamin D was the only one you can easily change - Sept 2023`
│   │   │   inner_content: `Multiple Sclerosis risk factors - Vitamin D was the only one you can easily change - Sept 2023`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── ListItemNode
│   full_match: `*((Multiple Sclerosis prevention with high-dose vitamin D (in rats in this case) - July 2023))`
│   inner_content: `((Multiple Sclerosis prevention with high-dose vitamin D (in rats in this case) - July 2023))`
│   depth: `1`
│   children:
│   ├── LocalLinkNode
│   │   full_match: `((Multiple Sclerosis prevention with high-dose vitamin D (in rats in this case) - July 2023))`
│   │   inner_content: `Multiple Sclerosis prevention with high-dose vitamin D (in rats in this case) - July 2023`
│   │   page: `Multiple Sclerosis prevention with high-dose vitamin D (in rats in this case) - July 2023`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Multiple Sclerosis prevention with high-dose vitamin D (in rats in this case) - July 2023`
│   │   │   inner_content: `Multiple Sclerosis prevention with high-dose vitamin D (in rats in this case) - July 2023`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── ListItemNode
│   full_match: `*((Diseases treated by high-dose Vitamin D - many studies))`
│   inner_content: `((Diseases treated by high-dose Vitamin D - many studies))`
│   depth: `1`
│   children:
│   ├── LocalLinkNode
│   │   full_match: `((Diseases treated by high-dose Vitamin D - many studies))`
│   │   inner_content: `Diseases treated by high-dose Vitamin D - many studies`
│   │   page: `Diseases treated by high-dose Vitamin D - many studies`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Diseases treated by high-dose Vitamin D - many studies`
│   │   │   inner_content: `Diseases treated by high-dose Vitamin D - many studies`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── ListItemNode
│   full_match: `*((An opportunity - use Vitamin D to treat Multiple Sclerosis (has been used for 14 years) - Feb 2022))`
│   inner_content: `((An opportunity - use Vitamin D to treat Multiple Sclerosis (has been used for 14 years) - Feb 2022))`
│   depth: `1`
│   children:
│   ├── LocalLinkNode
│   │   full_match: `((An opportunity - use Vitamin D to treat Multiple Sclerosis (has been used for 14 years) - Feb 2022))`
│   │   inner_content: `An opportunity - use Vitamin D to treat Multiple Sclerosis (has been used for 14 years) - Feb 2022`
│   │   page: `An opportunity - use Vitamin D to treat Multiple Sclerosis (has been used for 14 years) - Feb 2022`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `An opportunity - use Vitamin D to treat Multiple Sclerosis (has been used for 14 years) - Feb 2022`
│   │   │   inner_content: `An opportunity - use Vitamin D to treat Multiple Sclerosis (has been used for 14 years) - Feb 2022`├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!VitaminDWiki – ((Overview MS and vitamin D)) contains `
│   inner_content: `VitaminDWiki – ((Overview MS and vitamin D)) contains`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `VitaminDWiki – `
│   │   inner_content: `VitaminDWiki – `
│   ├── LocalLinkNode
│   │   full_match: `((Overview MS and vitamin D))`
│   │   inner_content: `Overview MS and vitamin D`
│   │   page: `Overview MS and vitamin D`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Overview MS and vitamin D`
│   │   │   inner_content: `Overview MS and vitamin D`
│   ├── TextNode
│   │   full_match: ` contains`
│   │   inner_content: ` contains`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── IncludeNode
│   full_match: `{include page=&quot;Overview MS and vitamin D&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}`
│   inner_content: ``
│   attrs_dict:
│   │   raw_content:  page=&quot;Overview MS and vitamin D&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;
│   │   page: Overview MS and vitamin D
│   │   start: ~tc~ start ~/tc~
│   │   stop: ~tc~ end ~/tc~
│   children:
│   ├── TextNode
│   │   full_match: ``
│   │   inner_content: ``├── TextNode
│   full_match: `\n\n`
│   inner_content: `\n\n`├── TikiCommentNode
│   full_match: `~tc~ (alias(Blood–brain barrier dysfunction in multiple sclerosis (improved by vitamin D, etc.) – Jan 2023)) ~/tc~`
│   inner_content: ` (alias(Blood–brain barrier dysfunction in multiple sclerosis (improved by vitamin D, etc.) – Jan 2023)) `
│   children:
│   ├── TextNode
│   │   full_match: ` (alias(Blood–brain barrier dysfunction in multiple sclerosis (improved by vitamin D, etc.) – Jan 2023)) `
│   │   inner_content: ` (alias(Blood–brain barrier dysfunction in multiple sclerosis (improved by vitamin D, etc.) – Jan 2023)) `

Original Tiki:
-------------
{DIV(class=&quot;lefth4&quot;)}{maketoc Title=&quot;&quot;}{DIV}
---
!!!!Blood–brain barrier dysfunction in multiple sclerosis: causes, consequences, and potential effects of therapies
Lancet January, 2024DOI:https://doi.org/10.1016/S1474-4422(23)00377-0 PDF behind paywall
Bettina Zierfuss, PhD, Catherine Larochelle, MD PhD, Prof Alexandre Prat, MD PhD 

Summary
Established by brain endothelial cells, the __blood–brain barrier__ (BBB) regulates the trafficking of molecules, restricts immune cell entry into the CNS, and has an active role in neurovascular coupling (the regulation of cerebral blood flow to support neuronal activity). In the early stages of multiple sclerosis, around the time of symptom onset, inflammatory BBB damage is accompanied by pathogenic immune cell infiltration into the CNS. In the later stages of multiple sclerosis, dysregulation of neurovascular coupling is associated with grey matter atrophy. 
Genetic and environmental factors associated with multiple sclerosis, including 
*dietary habits, 
*the gut microbiome, 
*and __vitamin D__ concentrations, 
might contribute directly and indirectly to brain endothelial cell dysfunction. Damage to brain endothelial cells leads to an influx of deleterious molecules into the CNS, accelerating leakage across the BBB. Potential future therapeutic approaches might help to prevent BBB damage (eg, monoclonal antibodies targeting cell adhesion molecules and fibrinogen) and help to repair BBB dysfunction (eg, mesenchymal stromal cells) in people with multiple sclerosis.
!!!!!101 References
1.Wengler K Ha J Syritsyna O et al.
Abnormal __blood–brain barrier__ water exchange in chronic multiple sclerosis lesions: a preliminary study.
Magn Reson Imaging. 2020; 70: 126-133
Scopus (7)
2.Freedman MS Devonshire V Duquette P et al.
Treatment optimization in multiple sclerosis: Canadian MS Working Group recommendations.
Can J Neurol Sci. 2020; 47: 437-455
Scopus (52)
3.Ramaglia V Rojas O Naouar I Gommerman JL
The ins and outs of central nervous system inflammation—lessons learned from multiple sclerosis.
Annu Rev Immunol. 2021; 39: 199-226
Scopus (22)
4.Proulx ST Engelhardt B
Central nervous system zoning: how brain barriers establish subdivisions for CNS immune privilege and immune surveillance.
J Intern Med. 2022; 292: 47-67
Scopus (16)
5.Bell AH Miller SL Castillo-Melendez M Malhotra A
The neurovascular unit: effects of brain insults during the perinatal period.
Front Neurosci. 2020; 131452
Scopus (79)
6.Spencer JI Bell JS DeLuca GC
Vascular pathology in multiple sclerosis: reframing pathogenesis around the __blood–brain barrier__.
J Neurol Neurosurg Psychiatry. 2018; 89: 42-52
Scopus (89)
7.Munji RN Soung AL Weiner GA et al.
Profiling the mouse brain endothelial transcriptome in health and disease models reveals a core __blood–brain barrier__ dysfunction module.
Nat Neurosci. 2019; 22: 1892-1902
Scopus (166)
8.Abadier M Lyck R
Pathways across the __blood–brain barrier__.
in: Lyck R Enzmann G The __blood–brain barrier__ and inflammation. Springer International Publishing, Cham2017: 187-211
9.Marchetti L Francisco D Soldati S et al.
ACKR1 favors transcellular over paracellular T-cell diapedesis across the __blood–brain barrier__ in neuroinflammation in vitro.
Eur J Immunol. 2022; 52: 161-177
Scopus (8)
10.Broux B Zandee S Gowing E et al.
Interleukin-26, preferentially produced by TH17 lymphocytes, regulates CNS barrier function.
Neurol Neuroimmunol Neuroinflamm. 2020; 7: e870
Scopus (16)
11.Charabati M Grasmuck C Ghannam S et al.
DICAM promotes TH17 lymphocyte trafficking across the __blood–brain barrier__ during autoimmune neuroinflammation.
Sci Transl Med. 2022; 14eabj0473
Scopus (18)
12.Fournier AP Tastet O Charabati M et al.
Single-cell transcriptomics identifies brain endothelium inflammatory networks in experimental autoimmune encephalomyelitis.
Neurol Neuroimmunol Neuroinflamm. 2022; 10e200046
13.Charabati M Zandee S Fournier AP et al.
MCAM+ brain endothelial cells contribute to neuroinflammation by recruiting pathogenic CD4+ T lymphocytes.
Brain. 2023; 146: 1483-1495
Scopus (5)
14.Fournier AP Zandee S Charabati M et al.
CLMP promotes leukocyte migration across brain barriers in multiple sclerosis.
Neurol Neuroimmunol Neuroinflamm. 2022; 9e200022
Scopus (3)
15.Michel L Grasmuck C Charabati M et al.
Activated leukocyte cell adhesion molecule regulates B lymphocyte migration across central nervous system barriers.
Sci Transl Med. 2019; 11eaaw0475
Scopus (38)
16.Wimmer I Tietz S Nishihara H et al.
PECAM-1 stabilizes __blood–brain barrier__ integrity and favors paracellular T-cell diapedesis across the __blood–brain barrier__ during neuroinflammation.
Front Immunol. 2019; 10: 711
Scopus (102)
17.Larochelle C Uphaus T Broux B et al.
EGFL7 reduces CNS inflammation in mouse.
Nat Commun. 2018; 9: 819
Scopus (29)
18.Goasdoué K Miller SM Colditz PB Björkman ST
Review: the __blood–brain barrier__; protecting the developing fetal brain.
Placenta. 2017; 54: 111-116
Scopus (89)
19.Delaney C Campbell M
The __blood–brain barrier__: insights from development and ageing.
Tissue Barriers. 2017; 5e1373897
Scopus (21)
20.Skillbäck T Blennow K Zetterberg H et al.
Sex differences in CSF biomarkers for neurodegeneration and __blood–brain barrier__ integrity.
Alzheimers Dement (Amst). 2021; 13e12141
21.Stamatovic SM Martinez-Revollar G Hu A Choi J Keep RF Andjelkovic AV
Decline in Sirtuin-1 expression and activity plays a critical role in __blood–brain barrier__ permeability in aging.
Neurobiol Dis. 2019; 126: 105-116
Scopus (80)
22.Li Y Xie L Huang T et al.
Aging Neurovascular unit and potential role of dna damage and repair in combating vascular and neurodegenerative disorders.
Front Neurosci. 2019; 13: 778
Scopus (3)
23.Dobi A Rosanaly S Devin A et al.
Advanced glycation end-products disrupt brain microvascular endothelial cell barrier: the role of mitochondria and oxidative stress.
Microvasc Res. 2021; 133104098
Scopus (19)
24.D&#39;Souza A Burch A Dave KM et al.
Microvesicles transfer mitochondria and increase mitochondrial function in brain endothelial cells.
J Control Release. 2021; 338: 505-526
Scopus (52)
25.Baranzini SE Oksenberg JR
The genetics of multiple sclerosis: from 0 to 200 in 50 years.
Trends Genet. 2017; 33: 960-970
Scopus (136)
Summary
Full Text
Full Text PDF
26.Jeong H-W Diéguez-Hurtado R Arf H et al.
Single-cell transcriptomics reveals functionally specialized vascular endothelium in brain.
eLife. 2022; 11e57520
27.Mohammadhosayni M Khosrojerdi A Lorian K et al.
Matrix metalloproteinases (MMPs) family gene polymorphisms and the risk of multiple sclerosis: systematic review and meta-analysis.
BMC Neurol. 2020; 20: 218
Scopus (10)
28.Patsopoulos NA Baranzini SE Santaniello A et al.
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility.
Science. 2019; 365eaav7188
29.Logsdon AF Erickson MA Rhea EM Salameh TS Banks WA
Gut reactions: how the __blood–brain barrier__ connects the microbiome and the brain.
Exp Biol Med (Maywood). 2018; 243: 159-165
Scopus (150)
30.Rhea EM Salameh TS Logsdon AF Hanson AJ Erickson MA Banks WA
__blood–brain barrier__s in obesity.
AAPS J. 2017; 19: 921-930
Scopus (85)
31.Zhou X Baumann R Gao X et al.
Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course.
Cell. 2022; 185: 3467-3486
Scopus (46)
Summary
Full Text
Full Text PDF
32.Cantoni C Lin Q Dorsett Y et al.
Alterations of host–gut microbiome interactions in multiple sclerosis.
EBioMedicine. 2022; 76103798
Scopus (43)
Summary
Full Text
Full Text PDF
33.Bäcker-Koduah P Bellmann-Strobl J Scheel M et al.
__vitamin D__ and disease severity in multiple sclerosis-baseline data from the randomized controlled trial (EVIDIMS).
Front Neurol. 2020; 11: 129
Scopus (11)
34.Cortese M Munger KL Martínez-Lapiscina EH et al.
__vitamin D__, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT.
Neurology. 2020; 94: e1950-e1960
Scopus (31)
35.Hupperts R Smolders J Vieth R et al.
Randomized trial of daily high-dose __vitamin D3__ in patients with RRMS receiving subcutaneous interferon β-1a.
Neurology. 2019; 93: e1906-e1916
Scopus (74)
36.Bjornevik K Cortese M Healy BC et al.
Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.
Science. 2022; 375: 296-301
Scopus (647)
37.Tengvall K Huang J Hellström C et al.
Molecular mimicry between anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk.
Proc Natl Acad Sci USA. 2019; 116: 16955-16960
Scopus (86)
38.Lanz TV Brewer RC Ho PP et al.
Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM.
Nature. 2022; 603: 321-327
Scopus (251)
39.Zhang N Zuo Y Jiang L Peng Y Huang X Zuo L
Epstein-Barr virus and neurological diseases.
Front Mol Biosci. 2022; 8816098
Scopus (40)
40.Montgomery S Hiyoshi A Burkill S Alfredsson L Bahmanyar S Olsson T
Concussion in adolescence and risk of multiple sclerosis.
Ann Neurol. 2017; 82: 554-561
Scopus (37)
41.Degelman ML Herman KM
Smoking and multiple sclerosis: a systematic review and meta-analysis using the Bradford Hill criteria for causation.
Mult Scler Relat Disord. 2017; 17: 207-216
Scopus (91)
Summary
Full Text
Full Text PDF
42.Wu S-Y Xing F Sharma S et al.
Nicotine promotes brain metastasis by polarizing microglia and suppressing innate immune function.
J Exp Med. 2020; 217e20191131
Scopus (48)
43.Oakes JM Fuchs RM Gardner JD Lazartigues E Yue X
Nicotine and the renin–angiotensin system.
Am J Physiol Regul Integr Comp Physiol. 2018; 315: R895-R906
Scopus (199)
44.Olsson T Barcellos LF Alfredsson L
Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis.
Nat Rev Neurol. 2017; 13: 25-36
Scopus (636)
45.Zhang SL Yue Z Arnold DM Artiushin G Sehgal A
A circadian clock in the __blood–brain barrier__ regulates xenobiotic efflux.
Cell. 2018; 173: 130-139.e10
Scopus (131)
Summary
Full Text
Full Text PDF
46.Cuddapah VA Zhang SL Sehgal A
Regulation of the __blood–brain barrier__ by circadian rhythms and sleep.
Trends Neurosci. 2019; 42: 500-510
Scopus (99)
Summary
Full Text
Full Text PDF
47.Artiushin G Zhang SL Tricoire H Sehgal A
Endocytosis at the Drosophila __blood–brain barrier__ as a function for sleep.
eLife. 2018; 7e43326
Scopus (49)
48.Sun J Wu J Hua F Chen Y Zhan F Xu G
Sleep deprivation induces cognitive impairment by increasing __blood–brain barrier__ permeability via CD44.
Front Neurol. 2020; 11563916
Scopus (22)
49.Nishihara H Perriot S Gastfriend BD et al.
Intrinsic __blood–brain barrier__ dysfunction contributes to multiple sclerosis pathogenesis.
Brain. 2022; 145: 4334-4348
Scopus (24)
50.Filippi M Brück W Chard D et al.
Association between pathological and MRI findings in multiple sclerosis.
Lancet Neurol. 2019; 18: 198-210
Scopus (144)
Summary
Full Text
Full Text PDF
51.Yong HYF Yong VW
Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis.
Nat Rev Neurol. 2022; 18: 40-55
Scopus (40)
52.Petersen MA Ryu JK Akassoglou K
Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics.
Nat Rev Neurosci. 2018; 19: 283-301
Scopus (256)
53.Yates RL Esiri MM Palace J Jacobs B Perera R DeLuca GC
Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex.
Ann Neurol. 2017; 82: 259-270
Scopus (77)
54.Ryu JK Rafalski VA Meyer-Franke A et al.
Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration.
Nat Immunol. 2018; 19: 1212-1223
Scopus (118)
55.Willis CM Nicaise AM Menoret A et al.
Extracellular vesicle fibrinogen induces encephalitogenic CD8+ T cells in a mouse model of multiple sclerosis.
Proc Natl Acad Sci USA. 2019; 116: 10488-10493
Scopus (30)
56.Brailoiu E Shipsky MM Yan G Abood ME Brailoiu GC
Mechanisms of modulation of brain microvascular endothelial cells function by thrombin.
Brain Res. 2017; 1657: 167-175
Scopus (40)
57.Suthiphosuwan S Sati P Absinta M et al.
Paramagnetic rim sign in radiologically isolated syndrome.
JAMA Neurol. 2020; 77: 653-655
Scopus (32)
58.Hagemeier J Ramanathan M Schweser F et al.
Iron-related gene variants and brain iron in multiple sclerosis and healthy individuals.
Neuroimage Clin. 2017; 17: 530-540
Scopus (27)
59.Sweeney MD Zhao Z Montagne A Nelson AR Zlokovic BV
__blood–brain barrier__: from physiology to disease and back.
Physiol Rev. 2019; 99: 21-78
Scopus (1043)
60.Benedict RHB Amato MP DeLuca J Geurts JJG
Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues.
Lancet Neurol. 2020; 19: 860-871
Scopus (237)
Summary
Full Text
Full Text PDF
61.Granziera C Wuerfel J Barkhof F et al.
Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis.
Brain. 2021; 144: 1296-1311
Scopus (58)
62.Sivakolundu DK West KL Maruthy GB et al.
Reduced arterial compliance along the cerebrovascular tree predicts cognitive slowing in multiple sclerosis: Evidence for a neurovascular uncoupling hypothesis.
Mult Scler. 2020; 26: 1486-1496
Scopus (13)
63.Barro C Benkert P Disanto G et al.
Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.
Brain. 2018; 141: 2382-2391
Scopus (300)
64.Uher T McComb M Galkin S et al.
Neurofilament levels are associated with __blood–brain barrier__ integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis.
Mult Scler. 2021; 27: 220-231
Scopus (41)
65.Sejbaek T Nielsen HH Penner N et al.
Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients.
J Neurol Neurosurg Psychiatry. 2019; 90: 1324-1330
66.Kuhle J Plavina T Barro C et al.
Neurofilament light levels are associated with long-term outcomes in multiple sclerosis.
Mult Scler. 2020; 26: 1691-1699
Scopus (57)
67.Hyun J-W Kim Y Kim G Kim S-H Kim HJ
Longitudinal analysis of serum neurofilament light chain: a potential therapeutic monitoring biomarker for multiple sclerosis.
Mult Scler. 2020; 26: 659-667
Scopus (21)
68.Sandelius Å Zetterberg H Blennow K et al.
Plasma neurofilament light chain concentration in the inherited peripheral neuropathies.
Neurology. 2018; 90: e518-e524
Scopus (162)
69.Kalm M Boström M Sandelius Å et al.
Serum concentrations of the axonal injury marker neurofilament light protein are not influenced by __blood–brain barrier__ permeability.
Brain Res. 2017; 1668: 12-19
Scopus (44)
70.Watanabe M Nakamura Y Michalak Z et al.
Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.
Neurology. 2019; 93: e1299-e1311
Scopus (112)
71.Papa L Ladde JG O&#39;Brien JF et al.
Evaluation of glial and neuronal blood biomarkers compared with clinical decision rules in assessing the need for computed tomography in patients with mild traumatic brain injury.
JAMA Netw Open. 2022; 5e221302
Scopus (14)
72.Brambilla R
The contribution of astrocytes to the neuroinflammatory response in multiple sclerosis and experimental autoimmune encephalomyelitis.
Acta Neuropathol. 2019; 137: 757-783
Scopus (139)
73.Martinsen V Kursula P
Multiple sclerosis and myelin basic protein: insights into protein disorder and disease.
Amino Acids. 2022; 54: 99-109
Scopus (42)
74.Nohejlova H Kayserova J Capek V Toman T Krsek P Liba Z
Paediatric onset of multiple sclerosis: analysis of chemokine and cytokine levels in the context of the early clinical course.
Mult Scler Relat Disord. 2020; 46102467
Scopus (5)
Summary
Full Text
Full Text PDF
75.Wang D Duan H Feng J et al.
Soluble CD146, a cerebrospinal fluid marker for neuroinflammation, promotes __blood–brain barrier__ dysfunction.
Theranostics. 2020; 10: 231-246
Scopus (21)
76.Ziliotto N Lamberti N Manfredini F et al.
Baseline and overtime variations of soluble adhesion molecule plasma concentrations are associated with mobility recovery after rehabilitation in multiple sclerosis patients.
J Neuroimmunol. 2021; 352577473
Scopus (2)
Summary
Full Text
Full Text PDF
77.Fournier AP Quenault A Martinez de Lizarrondo S et al.
Prediction of disease activity in models of multiple sclerosis by molecular magnetic resonance imaging of P-selectin.
Proc Natl Acad Sci USA. 2017; 114: 6116-6121
Scopus (37)
78.Masuda H Mori M Uchida T Uzawa A Ohtani R Kuwabara S
Soluble CD40 ligand contributes to __blood–brain barrier__ breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder.
J Neuroimmunol. 2017; 305: 102-107
Scopus (32)
Summary
Full Text
Full Text PDF
79.Agah E Zardoui A Saghazadeh A Ahmadi M Tafakhori A Rezaei N
Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: a systematic review and meta-analysis.
PLoS One. 2018; 13e0190252
Scopus (52)
80.Spitzer D Puetz T Armbrust M et al.
Anti-osteopontin therapy leads to improved edema and infarct size in a murine model of ischemic stroke.
Sci Rep. 2022; 1220925
Scopus (2)
81.Clemente N Comi C Raineri D et al.
Role of anti-osteopontin antibodies in multiple sclerosis and experimental autoimmune encephalomyelitis.
Front Immunol. 2017; 8: 321
Scopus (29)
82.Çiçekli E Sayan S Kotan D
Availability of fibrinogen/albumin ratio in MS attack.
Mult Scler Relat Disord. 2022; 60103674
Scopus (4)
Summary
Full Text
Full Text PDF
83.Miranda Acuña J Hidalgo de la Cruz M Ros AL Tapia SP Martínez Ginés ML de Andrés Frutos CD
Elevated plasma fibrinogen levels in multiple sclerosis patients during relapse.
Mult Scler Relat Disord. 2017; 18: 157-160
Scopus (17)
Summary
Full Text
Full Text PDF
84.Schaller-Paule MA Yalachkov Y Steinmetz H et al.
Analysis of CSF D-dimer to identify intrathecal fibrin-driven autoimmunity in patients with multiple sclerosis.
Neurol Neuroimmunol Neuroinflamm. 2022; 9e1150
Scopus (5)
85.Balasa R Barcutean L Mosora O Manu D
Reviewing the significance of __blood–brain barrier__ disruption in multiple sclerosis pathology and treatment.
Int J Mol Sci. 2021; 228370
Scopus (40)
86.Pyka-Fosciak G Lis GJ Litwin JA
Effect of natalizumab treatment on metalloproteinases and their inhibitors in a mouse model of multiple sclerosis.
J Physiol Pharmacol. 2020; 71: 265-273
87.Knudsen MH Lindberg U Frederiksen JL et al.
__blood–brain barrier__ permeability changes in the first year after alemtuzumab treatment predict 2-year outcomes in relapsing-remitting multiple sclerosis.
Mult Scler Relat Disord. 2022; 63103891
Scopus (5)
Summary
Full Text
Full Text PDF
88.Nguyen K Juillard P Hawke S Grau GE Marsh-Wakefield F
Trans-endothelial migration of memory T Cells is impaired in alemtuzumab-treated multiple sclerosis patients.
J Clin Med. 2022; 116266
Scopus (1)
89.Ford RK Juillard P Hawke S Grau GE Marsh-Wakefield F
Cladribine reduces trans-endothelial migration of memory T cells across an in vitro __blood–brain barrier__.
J Clin Med. 2022; 116006
Scopus (4)
90.Sellebjerg F Blinkenberg M Sorensen PS
Anti-CD20 monoclonal antibodies for relapsing and progressive multiple sclerosis.
CNS Drugs. 2020; 34: 269-280
Scopus (42)
91.Krämer J Bar-Or A Turner TJ Wiendl H
Bruton tyrosine kinase inhibitors for multiple sclerosis.
Nat Rev Neurol. 2023; 19: 289-304
Scopus (9)
92.Banoth B Cassel SL
Bruton tyrosine kinase inhibition: clinical relevance beyond B cells.
J Allergy Clin Immunol. 2017; 140: 985-987
Scopus (8)
Summary
Full Text
Full Text PDF
93.Mizuno M Noto D Kaga N Chiba A Miyake S
The dual role of short fatty acid chains in the pathogenesis of autoimmune disease models.
PLoS One. 2017; 12e0173032
Scopus (149)
94.Dai Y Wei T Shen Z Bei Y Lin H Dai H
Classical HDACs in the regulation of neuroinflammation.
Neurochem Int. 2021; 150105182
Scopus (16)
95.Shen Y Yang R Zhao J et al.
The histone deacetylase inhibitor belinostat ameliorates experimental autoimmune encephalomyelitis in mice by inhibiting TLR2/MyD88 and HDAC3/NF-κB p65-mediated neuroinflammation.
Pharmacol Res. 2022; 176105969
Scopus (15)
96.Buonvicino D Ranieri G Chiarugi A
Treatment with non-specific HDAC inhibitors administered after disease onset does not delay evolution in a mouse model of progressive multiple sclerosis.
Neuroscience. 2021; 465: 38-45
Scopus (6)
Summary
Full Text
Full Text PDF
97.Ghaiad HR Nooh MM El-Sawalhi MM Shaheen AA
Resveratrol promotes remyelination in cuprizone model of multiple sclerosis: biochemical and histological study.
Mol Neurobiol. 2017; 54: 3219-3229
Scopus (85)
98.Boffa G Lapucci C Sbragia E et al.
Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab.
Eur J Neurol. 2020; 27: 2047-2055
Scopus (13)
99.Roudi S Rädler JA El Andaloussi S
Therapeutic potential of extracellular vesicles in neurodegenerative disorders.
Handb Clin Neurol. 2023; 193: 243-266
Scopus (0)
100.Hayakawa K Chan SJ Mandeville ET et al.
Protective effects of endothelial progenitor cell-derived extracellular mitochondria in brain endothelium.
Stem Cells. 2018; 36: 1404-1410
Scopus (91)
101.Charabati M Rabanel J-M Ramassamy C Prat A
Overcoming the brain barriers: from immune cells to nanoparticles.
Trends Pharmacol Sci. 2020; 41: 42-54
Scopus (27)
---
!!!!28,000 hits for &quot;blood brain barrier&quot; &quot;vitamin d&quot; in Google Scholar
__https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C48&amp;q=%22blood+brain+barrier%22+%22vitamin+d%22&amp;btnG=|Google Scholar]__
*Active form of vitamin D directly protects the blood–brain barrier in multiple sclerosis-  August 2017 https://doi.org/10.1111/cen3.12398  FREE PDF
*Full spectrum of vitamin D immunomodulation in multiple sclerosis: mechanisms and therapeutic implications - June 2022  https://doi.org/10.1093/braincomms/fcac171 FREE PDF
**&quot;In this review, we focus on recent published data describing the biological effects of Vitamin D in animal models of multiple sclerosis on immune cells, blood–brain barrier function, activation of glial cells and its potential neuroprotective effects.&quot;
*The Role of Vitamin D in Neuroprotection in Multiple Sclerosis: An Update - June 2023  https://doi.org/10.3390/nu15132978 FREE PDF
*Intranasal administration of vitamin D attenuates blood–brain barrier disruption through endogenous upregulation of osteopontin and activation of CD44/P-gp glycosylation signaling after subarachnoid hemorrhage in rats - Oct 2016 https://doi.org/10.1177/0271678X16671147 FREE PDF
**Note: VitaminDWiki has been successfully experimenting in inhaing Vitamin D since about 2015
---
!!!!VitaminDWiki – ((Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019))
{include page=&quot;Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}
---
!!!!See Brain in VitaminDWiki 
*((Brain and Vitamin D - many studies))
*((Global burden of brain disorders surpasses cardiovascular disease and cancer - July 2023))
**Contains: Vitamin D inhaled thru the nose gets some directly to the brain
*((Vitamin D3 Attenuates Blood-Brain Barrier Disruption due to TBI (in rats) – Feb 2021))
*((Many Neurological Diseases fought by Vitamin D - Dec 2022))
---
!!!!See also in VitaminDWiki 
*((Multiple Sclerosis risk factors - Vitamin D was the only one you can easily change - Sept 2023))
*((Multiple Sclerosis prevention with high-dose vitamin D (in rats in this case) - July 2023))
*((Diseases treated by high-dose Vitamin D - many studies))
*((An opportunity - use Vitamin D to treat Multiple Sclerosis (has been used for 14 years) - Feb 2022))
---
!!!!VitaminDWiki – ((Overview MS and vitamin D)) contains 
{include page=&quot;Overview MS and vitamin D&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}

~tc~ (alias(Blood–brain barrier dysfunction in multiple sclerosis (improved by vitamin D, etc.) – Jan 2023)) ~/tc~
</code>
</pre>
